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Acute myeloid leukemia (AML) is a heterogeneous disease, characterized by recurrent genetic 
mutations. Mutations in the cohesin complex are one of the 8 functional categories of mutations 
in AML. SMC3 encodes a subunit of the cohesin complex, which has important roles in 
chromosome segregation, genome instability, and gene expression. In the first chapter of the 
dissertation, we discuss the genetics of AML, normal functions of the cohesin complex, and the 
interplay between cohesin mutations and myeloid malignancies.  
 
SMC3 is recurrently mutated in AML and other myeloid malignancies. In the second chapter of 
the dissertation, we compare the consequences of Smc3 deficient and haploinsufficient mouse 
models to determine whether the heterozygous missense mutations in SMC3 might have 
dominant-negative effects or phenocopy loss-of-function effects. We found that homozygous 
deletion of Smc3 during embryogenesis or in adult mice resulted in hematopoietic failure. SMC3 
missense mutations are therefore unlikely to be associated with simple dominant negative 
phenotypes due to incompatibility with hematopoiesis. Smc3 haploinsufficiency, in contrast, was 
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tolerated during embryonic and adult hematopoiesis. Under steady-state conditions, Smc3 
haploinsufficiency did not alter colony forming capacity ex vivo and led to modest transcriptional 
and chromatin accessibility changes in Lin-cKit+ progenitor cells. However, following 
tamoxifen-induced deletion in competitive transplantations, we observed a significant 
hematopoietic competitive disadvantage in Smc3 haploinsufficient bone marrow cells across 
myeloid and lymphoid lineages and within the stem/progenitor compartments. The competitive 
disadvantage was not affected by different conditions of hematopoietic stresses, but was partially 
abrogated by concurrent Dnmt3a haploinsufficiency, suggesting that antecedent mutations may 
be the prerequisites to realize the leukemogenic potential of Smc3 mutations.   
 
In the third chapter of the dissertation, we present a case of an older women that initially 
appeared to be treatment-related AML following non-cytotoxic all-trans retinoic acid 
(ATRA)/arsenic trioxide (ATO) therapy for acute promyelocytic leukemia (APL), but upon 
further analysis found to be more consistent with secondary AML. Exome sequencing revealed a 
TET2-mutated dominant clonal process that preceded the APL diagnosis, persisted, and gave rise 
to an AML-associated new subclone with a NPM1 mutation. Review of additional cytogenetic 
abnormalities observed in APL patients showed that cytogenetic abnormalities commonly occur 
as subclones of the APL clone, although one rare case with del(7) independent of the APL clone 
was identified. These results demonstrated that APL may emerge within the context of clonal 
hematopoiesis and caution must be exercised when interpreting the development of tAML after 
ATRA/ATO therapy, especially in older patients.  
 
1 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1: 
Introduction 
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1.1 Acute Myeloid Leukemia (AML) 
1.1.1 Disease statistics 
Acute myeloid leukemia is an aggressive myeloid neoplasm characterized by accumulation of 
myeloblasts in the blood or bone marrow.1 Proliferating immature myeloblasts impair the 
development of normal hematopoiesis, leading to severe infections, cytopenias, anemia, immune 
compromise, and death.2 AML is the most common acute leukemia in adults, with 19,520 
estimated new cases in 2018, accounting for 1.1% of all new cancer cases in the US.3, 4 AML is 
slightly more common among men than women, and approximately 0.5% of the population will 
be affected at some point during their lifetime based on 2013-2015 data.4, 5 Although AML can 
occur in any age group, AML is primarily a disease of the elderly, with a median age at diagnosis 
of 68 years.5, 6 Advances in the treatment of AML have significantly improved the outcomes for 
younger adult patients, with 5-year survivals of 35 to 40% among those who are 60 years of age 
or younger.7 However, prognosis in older patients, who account for the majority of new cases, 
remains dismal, with 2-year survivals of only 5 to 15% among patients who are older than 60 
years of age, as much as 70% of the elderly will die within 1 year of diagnosis.7, 8 Across all age 
groups, the 5-year overall survival of AML is 27.4%, with an estimated 10,670 deaths in 2018, 
consisting of 1.8% of all cancer deaths in the US.4  
1.1.2 Genetics 
1.1.2.1 AML with recurrent genetic abnormalities 
AML is a heterogeneous disease. The cytogenetic heterogeneity of AML has been recognized for 
more than three decades. Based on karyotype analysis, AML with recurrent genetic 
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abnormalities can be divided into two subtypes: (1) AML with chromosomal aneuploidies; (2) 
AML with balanced genomic rearrangements.9 
AML with chromosomal aneuploidies  
Over 60% of cases in the subgroup of AML with chromosomal aneuploidies have at least 3 
chromosomal events, of which the most frequent are -5/5q, -7/7q, -12/12p, -17/17p, and +8/8q. 
Approximately 50% of patients with deletions in chromosomes 5, 7, 12, or 17 have TP53 
mutations, and these are more commonly observed in older patients; the median age of patients 
with chromosomal aneuploidy and TP53 mutations is 58 years vs. 49 years with aneuploidy 
alone.9 Patients with both complex karyotype and TP53 mutations have significantly inferior 
prognosis to the poor overall outcomes associated with either subset alone, but recent data by 
groups at Washington University in St. Louis suggest that this unique subgroup of AML may 
respond favorably to hypomethylating agent, decitabine.10  
AML with balanced genomic rearrangements 
AML with balanced genomic rearrangements tend to present at a younger age and have, on 
average, 1 genomic rearrangement and lower overall number of acquired mutations, most 
frequently concurrent with activating mutations FLT3- internal tandem duplication (ITD), KIT, 
NRAS, tyrosine or serine-threonine kinases, and protein tyrosine phosphatases.11 There are at 
least 7 distinct subtypes of recurrent genomic rearrangements in AML, each defining a 
clinicopathologic entity.12 These translocations and inversions are considered leukemia-initiating 
and are almost uniformly present in patients who subsequently relapse.  
The most common translocation fusion gene is PML-RARA, defined by t(15;17)(q22;q21), which 
occurs in 5-13% of patients and is characteristic of acute promyelocytic leukemia (APL). FLT3-
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ITD and WT1 mutations co-occur with PML-RARA in approximately 35% and 15% of APL 
cases, respectively. APL patients with PML-RARA that are FLT3 negative are associated with 
favorable outcomes when treated with combinational chemotherapy that includes all-trans-
retinoic acid (ATRA).13 Outcomes in APL patients treated with chemotherapy alone were 
historically dismal, demonstrating the adaptive relevance of mutation: treatment interactions.   
RUNX1-RUNXIT1 AML, defined by t(8;21)(q22;q22.1), occurs in 1-6% of patients, is associated 
with good risk following treatment with high dose cytarabine. KIT mutations co-occur with 
t(8;21) in approximately 25% of RUNX1-RUNXIT1 AML, and these patients have inferior 
outcomes compared to KIT wild type patients. 13, 14  
The CBFB-MYH11 fusion results from inv(16)(p13.1q22) and occurs in 1-6% of AML patients. 
CBFB-MYH11 AML also has favorable prognosis in the absence of KIT mutations. NRAS 
mutations co-occur with CBFB-MYH11 in approximately 40% of AML cases. The less frequent 
genomic rearrangements, affecting about 1% or less of AML patients include: MLLT3-KMT2A, 
defined by t (9;11)(p21.3;q23.3); DEK-NUP214, defined by t(6;9)(p23;q34.1); GATA2, 
MECOM, defined by inv(3)(q21.3q26.2), and RBM15-MKL1 ,defined by (t1;22)(p13.3;q13.3).9, 
13  
1.1.2.2 AML with gene mutations 
Over the past 15 years, advances in next-generation sequencing (NGS) have tremendously 
increased our knowledge of the molecular heterogeneity of AML. AML was the first primary 
cancer to be studied by massively-parallel sequencing technologies.15 In 2008, the first AML 
genome was published in a landmark study done by groups at Washington University in St. 
Louis.16 Subsequent studies have identified numerous novel recurrent somatic mutations with 
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biologic, prognostic, and therapeutic relevance and have demonstrated that AML is a complex 
and dynamic disease. Emerging data with the use of NGS are revolutionizing our view of the 
spectrum and frequency of mutations, their distinct patterns of cooperativity and mutual 
exclusivity, their subclonal architecture, the epigenetic landscape of the disease, and the clonal 
evolution during AML.17 
Clonal Evolution 
Studies have shown that most cases of AML are characterized by clonal heterogeneity at the time 
of diagnosis, with more than half of the patients exhibiting at least one subclone in addition to a 
founding clone.11 Data from clonal evolution studies provide support for a model that mutations 
in genes involved in epigenetic regulation (specifically genes involved in the regulation of DNA 
methylation and chromatin modifications, most commonly DNMT3A, TET2, IDH1, IDH2, and 
ASXL1) are present in preleukemic  hematopoietic stem cells (HSCs) and occur early in the 
evolution of AML, preceding secondary leukemogenic events such as mutations in 
nucelophosmin (NPM1) or signaling genes (FLT3, RAS).13, 17 Furthermore, the epigenetic 
modifying genes are frequently found to be mutated in elderly individuals along with clonal 
expansion of hematopoiesis that confers and increased risk for the development of hematologic 
cancers.13 Such ancestral preleukemic stem cells are capable of multilineage differentiation. For 
example, preleukemic DNMT3A-mutant HSCs were shown to have a multilineage repopulation 
advantage over wild type HSCs and were detected in samples collected from patients who were 
in morphologic complete remission, indicating their potential to be resistant and survive 
chemotherapy.18  Thus, preleukemic hematopoietic clones can persist over time, survive 
chemotherapy, expand during remission, and eventually leading to relapse and the various 
patterns of clonal composition that occur at relapse may contribute to resistance to therapy.19  
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Clonal Hematopoiesis 
Recent studies of large population-based cohorts show that clonal hematopoiesis with recurrent 
mutations in epigenetic regulators DNMT3A, TET2, and ASXL1 (and less frequently in splicing 
factor genes SRSF2, SF3B1 and in the genotoxic sensor TP53) increases as people age and 
confers an increased risk of hematologic cancer and death.20, 21, 22, 23, 24 Expanded clones 
containing these somatic mutations can be identified in the blood or bone marrow of patients 
without evidence of overt hematologic malignancy and decades before the development of AML. 
This defines a new entity, termed either “age-related clonal hematopoiesis” (ARCH) or “clonal 
hematopoiesis of indeterminate potential (CHIP)”, which has been identified in approximately 
10% of patients 70-80 years old.22, 23 A recent study conducted by groups at Washington 
University in St. Louis using bar-coded sequencing found a higher incidence of ARCH if the 
threshold of detection is lowered to 0.5%.25 The incidence of CHIP increases with age, 
predisposes patients to AML and other hematologic malignancies, including myelodysplastic 
syndromes (MDS), and the transformation rate of CHIP into a hematologic disease is about 0.5-
1% per year.26  
The Cancer Genome Atlas (TCGA) Project 
The Cancer Genome Atlas Research Network analyzed the mutational profiling of 200 patients 
with de novo AML by either whole-genome (n=50) or whole-exome (n=150) sequencing, along 
with RNA and microRNA expression and DNA methylation analysis.11 Significantly mutated 
genes in AML were organized into 8 functional categories, summarized in Figure 1.117. (1) 
Mutations in NPM1, encoding a multifunctional nucleo-cytoplasmic shuttling protein, resulting 
in the aberrant cytoplasmic localization of NPM1 and NPM1-interacting proteins; (2) Mutations 
in signaling genes such as kinases FLT3, KIT, or RAS family members KRAS, NRAS that confer 
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a proliferative advantage through the RAS-RAF, JAK-STAT, and PI3K-AKT signaling 
pathways; (3) Mutations in myeloid transcription factors such as RUNX1 and CEBPA, leading to 
transcriptional deregulation and impaired hematopoietic differentiation; (4) Mutations in tumor-
suppressor genes such as TP53 and WT1 that result in transcriptional deregulation and impaired 
degradation through the mouse double minute 2 homologue (MDM2) and the phosphatase and 
tensin homologue (PTEN); (5) Mutations in DNA methylation-associated genes DNMT3A and 
TET2 that deregulate DNA methylation patterns and lead to transcriptional deregulation of 
leukemia-associated gens or in IDH1 and IDH2 that act through the 2-hydroxyglutarate (2-HG) 
oncometabolite production and impact DNA methylation via impairment of TET2; (6) Mutations 
in chromatin-modifying genes such as AXL1 and PHF6, leading to deregulation of chromatin 
modification, for instance methylation of histones H3 and H2A; (7) Mutations in spliceosome-
complex genes such as SRSF2, SF3B1, U2AF1, and ZRSR2 that are involved in impaired 
spliceosome function and deregulated RNA processing; (8) Mutations in cohesin-complex genes 
such as SMC3, STAG2, and RAD21 that may impair accurate chromosome segregation and 
transcriptional regulation.17 
NPM1 mutations 
NPM1 encodes a phosphoprotein that normally shuttles between the nucleus and the cytoplasm 
and plays a role in in epigenetic control, ribosomal protein assembly, and regulation of p53 
tumor suppressor pathway.27 NPM1 mutations are the most common genetic mutations in AML, 
found in approximately 30% of all AML and 45-60% of AML with normal karyotype.17, 28 They 
are mutually exclusive to other genomic rearrangements and frequently co-exist with DNMT3A 
(approximately 50%), FLT3-ITD (approximately 40%), NRAS (approximately 20%), cohesin 
genes SMC3, SMC1A, RAD21 (approximately 20%), TET2 (approximately 15%), IDH1 
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(approximately 15%), IDH2R140 (approximately 15%) mutations, and PTPN11 (approximately 
15%).13 Mutations in DNA hydroxymethylation genes (DNMT3A, TET2, IDH1, and IDH2) 
typically represent the first acquired event and are present in the founding clone while NPM1 is 
acquired as a secondary event during leukemogenesis, together with mutations in FLT3, NRAS, 
and PTPN11. In younger patients (<60 years old), NPM1 mutations in cytogenetically normal 
AML without FLT3-ITD mutations portend a favorable prognosis.29 However, patients with 
concomitant mutations in NPM1, FLT3-ITD, and DNMT3A, which represent the most frequent 
triple genotype in AML, have significantly shorter event-free survival and inferior overall 
survival.9  
Mutations in signaling genes 
FLT3 encodes a receptor tyrosine kinase involved in hematopoiesis. There are two common 
mutations that occur in FLT3: ITD in the juxtamembrane domain and a point mutation of the 
tyrosine kinase domain (TKD), both mutations lead to constitutive activation. Approximately 
20% of all AML cases harbor a FLT3-ITD mutation, which is associated with an unfavorable 
prognosis and the mutation is more common in cytogenetically normal AML, accounting for 
approximately 30% of these cases.30 The frequency of FLT3-ITD mutations decreases with older 
age and FLT3 mutations are associated with NPM1 mutations.13 There is variability in the size of 
the FLT3-ITD, ranging from a few base pairs to over 1000 base pairs, the number of FLT3-ITD 
mutations, approximately 14-25% of FLT3-ITD positive patients will have more than one FLT3-
ITD mutation.31, 32 Sequencing of FLT3-ITD reveals that the sequence and site of the mutations 
are variable: in fact, only about two-thirds of the FLT3 mutations are true tandem duplications 
while the remaining are insertions or complex duplications and insertions; approximately 30% of 
FLT3-ITD occur outside the juxtamembrane domain and instead occur in the TKD, usually in the 
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β1 sheet.32, 33, 34 The less common FLT3-TKD mutation is found in approximately 10% of 
AML.28  
KIT encodes a receptor tyrosine kinase that plays important roles in proliferation, differentiation, 
and cell survival. The ligand for KIT is stem cell factor (SCF). Binding of SCF to the 
extracellular domain of KIT induces receptor dimerization and activation of downstream 
signaling pathways that are involved in mediating pro-growth and pro-survival signals within the 
cell, including the MAPK signaling pathway (RAS-RAF-MEK-ERK), the PI3K pathway (PI3K-
AKT-mTOR), and the STAT3 pathway.35 KIT mutations are gain-of-function mutations that 
occur in less than 5% of all AML cases and are higher, 25-35% of cases in core-binding factor 
leukemia.2, 30 KIT mutations occur primarily in exon 17 and affect the activation loop of the 
kinase domain, resulting in improved proliferation and survival of leukemic cells.36 KIT 
mutations confer unfavorable prognosis in AML with t(8;21), RUNX1-RUNXIT1 AML.13  
KRAS and NRAS belong to the RAS GTPase family of genes. KRAS mutations are less common 
in adults, found in only 2% of cases vs. 9% of cases in children.37, 38 NRAS mutations occur in 
approximately 15% of AML cases in adults and children.13 The concurrent mutations of NRAS 
are NPM1 and biallelic CEPBA. RAS mutations do not appear to have a clear impact on outcome 
except for NRASG12/G13, which confers superior outcomes in presence of NPM1 and DNMT3A 
mutations.39  
Mutations in myeloid transcription factors 
RUNX1 encodes the alpha subunit of the heterodimer core binding factor, which is involved in 
transcription.30 Somatic RUNX1 mutations occur in 5-20% of AML and the incidence increases 
with older age.2 They co-segregate with mutations in SRSF2 (approximately 25%), ASXL1 
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(approximately 20%), KMT2A (15-20%), IDH2R140 (approximately 12%).13 They are mutually 
exclusive with NPM1, biallelic CEBPA, and AML with recurrent cytogenetic abnormalities.9 
RUNX1 mutations are associated with male sex, inferior outcome, and secondary AML evolving 
from MDS.40 Germline RUNX1 mutations are found in the autosomal dominant familial platelet 
disorder, conferring a predisposition to AML.41  
CEBPA encodes a transcription factor involved in granulocytes differentiation. CEBPA 
mutations are found in approximately 10% of AML and are more common in cytogenetically 
normal AML or with 9q deletions.42 The incidence of CEBPA mutations declines with older age. 
Approximately 2/3 of CEBPA mutations may be biallelic, which usually include one N-terminus 
and one C-terminus mutation, leading to null expression of CEBPA, and the rest are monoallelic, 
which can be truncating N-terminal mutations resulting in a shortened CEBPA with a dominant 
negative effect or C-terminal mutations that decrease dimerization or DNA binding.43, 44, 45, 46 
Biallelic CEBPA mutations co-occur with NRAS (approximately 30%), GATA2 (approximately 
30%), WT1 (approximately 20%), CSF3R (approximately 20%), and 9q- (approximately 15%), 
and confer a favorable prognosis.13  
 
Mutations in tumor-suppressor genes 
TP53 is a tumor suppressor gene and frequently referred to as the “guardian of the genome” that 
regulates the cell cycle in response to cellular stresses. TP53 mutations occur in 5-20% of adult 
AML and approximately 1% of pediatric AML.13, 37 The incidence of TP53 mutations 
significantly increases with older age. TP53 mutations are predominantly detected in AML with 
complex karyotype (56-78% of cases) and are associated with very poor outcome in AML as in 
other cancers.17, 47  
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WT1 encodes a transcription factor important for normal cellular development and cell survival 
that appears to play a tumor suppressor role in renal tissues, but an oncogenic role in leukemia.48 
WT1 mutations can be found in 4-11% of AML cases and are linked with poor outcome in AML 
with a normal karyotype.30   
 
Mutations in DNA-methylation-associated genes 
DNMT3A encodes a DNA methyltransferase involved in the epigenetic regulation of the genome 
through methylation. DNMT3A mutations are quite common in AML, occurring in 
approximately 20% of patients and frequently co-occur with NPM1, FLT3-ITD, IDH1, IDH2, 
and SMC3 mutations.17, 49 The most common mutation is a substitution of arginine at position 
882 (R882).50 DNMT3A with heterozygous R882H mutation forms stable heterodimers with 
wild type DNMT3A, disrupting the ability of the wild type DNMT3A protein to form active 
tetramers and leading to a hypomorphic effect on the methyltransferase activity of the enzyme 
and also a dominant negative effect on the wild type DNMT3A.51, 52, 53 The incidence of 
DNMT3A mutations increases with older age. They are associated with CHIP and secondary 
AML evolving from MDS and are early events in leukemogenesis. The frequency of DNMT3A 
R882 mutations is less than one-third of CHIP DNMT3A mutations, but more than two-thirds of 
AML DNMT3A mutations. DNMT3A mutations have moderate adverse effect on outcome, which 
can be overcome by high doses anthracycline chemotherapy.47, 38  
TET2 encodes an epigenetic modifier that converts methylcytosine to 5-hydroxymethylcytosine 
and is also involved in myelopoiesis. TET2 mutations are found in 7-25% of adult AML and 1.5-
4% of pediatric AML and are early events in leukemogenesis. Mutations in TET2 are highly 
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variable, including nonsense mutations, deletions, missense mutations, and splice-site mutations, 
which all appear to cause loss-of-function and decrease hydroxymethylation of DNA.54 NPM1 
mutations and TET2 mutations statistically co-occur with FLT3-ITD and -TKD aberrations.55 In 
contrast, IDH mutations seldom co-exist with TET2 mutations possibly because 2-HG inhibits 
the activity of TET2 (see below).55, 56 The incidence of TET2 mutations in AML increases with 
older age and TET2 mutations have been found in healthy elderly individuals with CHIP.20  
IDH1 and IDH2 are genes involved in metabolism and may also play an epigenetic role in 
histone and DNA methylation.57 Mutations in IDH1 and IDH2 occur at the active isocitrate 
binding site, which alters the enzymatic activity and leads to the generation of a novel 
oncometabolite, 2-HG.58 IDH mutations statistically co-occur with NPM1 mutations (except for 
IDH2R172).59 They are associated with CHIP in healthy elderly individuals (although much less 
commonly than DNMT3A, TET2, ASXL1, and TP53 mutations) and are early events in 
leukemogenesis.13 IDH1 mutations affect the arginine at position 132 or 170 (R132 or R170) and 
can be found in 7-14% of adult AML cases, but only 1% of pediatric AML.17, 37 These mutations 
are mutually exclusive and exclusive of the IDH2 mutations. IDH1 mutations are associated with 
unfavorable outcome.60 IDH2 mutations affect the arginine at position 140 or 172 (R140 or 
R172) and occur in 8-19% of adult AML, but only 1-2% of pediatric cases.17, 61 The incidence of 
IDH2R140 mutation increases with older age and has been shown to have a favorable prognosis in 
intermediate risk AML with NPM1 mutations.38 
Mutations in chromatin-modifying genes 
ASXL1 encodes a chromatin binding protein, which regulates gene transcription in localized 
areas via modifying chromatin structure. ASXL1 mutations are frequently found in MDS and 
AML, with a frequency of 5-15%, but appear to be enriched in secondary AML and intermediate 
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risk AML.62 ASXL1 mutations are associated with male sex and CHIP in healthy elderly people 
and they also increase with older age, more prevalent in patients over 60 years old and quite rare 
(approximately 1%) in children.23, 63 Frequent concomitant mutations are RUNX1 (approximately 
20%), IDH2R140 (approximately 13%), and SRSF2.13 ASXL1 mutations are early events in 
leukemogenesis, with most studies showing they are predictive of inferior outcome, particularly 
genotypes ASXL1mut/RUNX1mut and ASXL1mut/SRSF2mut.17 
PHF6 is an X-linked gene that appears to be a highly dynamic chromatin adaptor protein that 
interacts with a growing number of partners (nucleosome remodeling and deacetylation complex, 
PAF1, UBF) to regulate transcription.64 Germline loss-of-function mutations in PHF6 are the 
cause of the Börjeson-Forssman-Lehmann X-linked intellectual disability syndrome.65 Somatic 
PHF6 mutations occur in 2-3% of adult AML and are more frequent in males than females.66, 67 
They are associated with adverse prognosis in intermediate risk AML patients who are negative 
for FLT3-ITD.38   
Mutations in spliceosome-complex genes 
Mutations in splicing factor genes SRSF2, SF3B1, U2AF1, and ZRSR2 lead to impaired 
spliceosome function and deregulated RNA processing resulting in aberrant splicing patterns. 
Mutations in spliceosome-complex genes account for 14% of AML patients in the TCGA 
cohort.11 They are associated with CHIP in healthy elderly persons and poor outcome, shown by 
a few studies on clinical significance.13 Moreover, mutations of splicing factors occur in high 
frequencies in MDS. Refractory anemia with ringed sideroblasts (RARS) is a subtype of MDS 
characterized by the accumulation of erythroid precursor cells and 15% or more ring sideroblasts 
in the bone marrow. SF3B1 is highly mutated in RARS, whereas U2AF1 mutations are not 
linked with ringed sideroblasts and RARS.68 
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SRSF2 mutations are also found in chronic myelomonocytic leukemia (CMML) and confer an 
increased risk of transformation to acute leukemia. Mutations can occur in multiple domains, 
although the most recurrent mutations affect the RNA recognition motif and arginine/serine-rich 
protein interaction domain of the protein.69, 70 Functional studies have shown that the P95 SRSF2 
mutations have an altered RNA-binding activity resulting in mis-splicing of many important 
genes including EZH2.71  
SF3B1 is the most commonly mutated spliceosomal gene in hematological cancers, including 
MDS, with almost half of SF3B1 mutations in lysine 700. Heterozygous SF3B1 mutations are 
mostly missense substitutions in addition to hotspots in the HEAT repeat domains.71  
U2AF1 is frequently mutated in codons S34 and Q157 in approximately 11% of MDS patients. 
Heterozygous insertions and deletions have also been reported.72, 73 U2AF1 mutations appear to 
interfere with 3’ splice site binding function of the protein, leading to aberrant alternative 
splicing of numerous U2-dependent introns potentially and constructing an entirely novel 
transcriptome specific to MDS.74  
ZRSR2 mutations are distributed throughout the gene in MDS patients, interrupting the coding 
capacity by creating in-frame stop codons and therefore suggestive of loss-of-function 
phenotypes.72 Knockdown of ZRSR2 revealed a distinct splicing defect pattern of the U12-
dependent introns, affecting a large number of U12-type intron-containing genes that play a 
significant role in MAPK signaling pathways and E2F transcription activities, and impaired in 
vitro erythroid differentiation while promoted myeloid differentiation of cord blood-derived 
CD34+ cells, which supports MDS phenotype.75  
Mutations in cohesin-complex genes 
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Mutations in cohesin complex genes SMC3, STAG2, RAD21, and SMC1A may cause defects in 
chromatid cohesion or impact transcriptional regulation. Cohesin mutations occurred in about 
10% of non-M3 AML cases and were identified in 13% of AML patients in the TCGA cohort.11, 
49 Cohesin mutations frequently co-occur with NPM1 mutations and RUNX1-RUNXIT1. Other 
common mutations concurrent with cohesin mutations in AML include RAS, RUNX1, TET2, 
ASXL1, and EZH2.11, 39, 76 Cohesin mutations are not only found in AML, but also in other 
myeloid malignancies such as CMML, chronic myeloid leukemia (CML), myeloproliferative 
neoplasms (MPNs), and MDS.77, 78 Notably, more than 50% of patients with Down syndrome-
associated acute megakaryocytic leukemia (DS-AMKL) have mutations in STAG2, which can 
co-occur with mutations in RAS, ASXL1, EZH2, JAK2, and JAK3.79  
SMC3 and RAD21 mutations are nearly universally heterozygous and the majority of SMC3 
mutations are missense mutations. Intriguingly, SMC3 mutations frequently co-occur with 
DNMT3A mutations, one of the most commonly mutated genes in AML. STAG2 and SMC1A are 
encoded on the X chromosome, and therefore mutations would be thought to result in null 
alleles.80 Additionally, cohesin mutations tend to be mutually exclusive, implying that either they 
may not be tolerated by a cell when co-occurring or alteration in one component may be 
sufficient to disrupt the entire complex.49, 76 Although cohesin mutations are often observed as 
early subclonal events during leukemia development, conceivably facilitating disease initiation, 
they are not observed in CHIP; thus, they are unlikely to be the initiating event.21, 81, 82 In most 
AML cases, cohesin mutations are not associated with karyotypic abnormalities, suggesting 
cohesin mutations contribute to leukemogenesis through alternative pathways other than 
inducing genomic instability.11, 76 
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This thesis focuses on understanding the contribution of cohesin mutations, particularly SMC3 
mutations to the pathogenesis of AML.  
1.2 Cohesin in Cancer 
1.2.1 Roles of cohesin 
The cohesin complex consists of four core subunits, structural maintenance of chromosomes 
(SMC) proteins SMC1A and SMC3, RAD21, and STAG.83 In mammals, there are two related 
STAG proteins, STAG1 or STAG2. Both SMC proteins are rod-shaped proteins containing ATP-
binding cassette (ABC)-like ATPase motifs and are characterized by a globular hinge domain 
flanked by two alpha-helical domains, which fold back on themselves at the hinge, forming a 
long antiparallel coiled coil arm that brings the N- and C-termini together. SMC1A and SMC3 
form a V-shaped heterodimer at the hinge domains. At the distal end of the two coiled coil arms, 
the N- and C-termini of each SMC protein form an ATPase head domain.84 The kleisin family 
protein RAD21 physically connects the ATPase heads of SMC1A and SMC3, thus forming a 
tripartite ring-like structure, with an internal diameter of about 40nm.85 The STAG subunit 
interacts with RAD21 and further stabilizes the cohesin ring. In addition to the four core 
subunits, cohesin loaders (Scc2/NIPBL, Scc4/MAU2), cohesin regulators (PDS5, SORORIN, 
and WAPL), cohesin protector (SGOL), and cohesin modifiers (ESCO and HDAC8) also bind to 
or modify the cohesin complex (Figure 1.2).86 
The cohesin complex is highly conserved through evolution with homologs in yeast, fruit flies, 
and mammals (Table 1.184).87 Among the several models have been proposed to depict how the 
cohesin complex associates with chromatin, the one-ring “embrace” model and the two-ring 
“handcuff” model are supported by experimental data.88, 89 The one-ring model suggests that the 
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cohesin ring embraces two chromatins until their segregation.88 The two-ring model describes 
each cohesin ring entraps one chromatin and cohesion is mediated by interactions between the 
two cohesin rings.89 The canonical role of the cohesin complex is to ensure proper segregation of 
chromosomes during mitosis and meiosis. In addition to its essential role in sister chromatids 
cohesion, cohesin contributes to genome maintenance and functions by involving in DNA 
damage repair and gene expression.90  
1.2.1.1 Cohesin functions in chromosome segregation 
Cohesins are loaded to the chromatins at the G1/S phase in yeast and at telophase in mammalian 
cells by loading complex NIPBL-MAU2.91, 92, 93, 94, 95 During DNA replication at S phase, each 
cohesin ring embraces one of the sister chromatids. After DNA replication at the S phase, 
acetylation of SMC3 by cohesin acetyltransferases ESCO1 and ESCO2 establishes stable 
cohesion between the newly replicated sister chromatids. PDS5 and SORORIN form a complex 
to maintain the cohesion throughout the G2 phase until prophase when SORORIN is 
phosphorylated and destabilized.96, 97, 98, 99 The removal of cohesins are facilitated by the 
formation of PDS5-WAPL complex. At prophase, cohesins on the chromosomal arms are 
removed by the phosphorylation of RAD21 and STAG1/2 by PLK1.100 Centromeric cohesion is 
protected by SGOL1 until Separase gets activated and cleaves RAD21 at anaphase and therefore 
separating the sister chromatids.101, 102 The dissociated cohesins can be recycled after the acetyl 
groups are removed from SMC3 proteins by cohesin deacetylases HDAC8.103, 104 In meiosis, a 
similar biphasic removal of cohesin occurs, with RAD21 replaced by REC8.105  
The main roles of cohesin during cell cycle are to keep sister chromatids together and to provide 
resistance when sister chromatids are pulled by microtubules towards the opposing spindle poles, 
thus ensuring accurate separation of sister chromatids during the transition from metaphase to 
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anaphase.106 Failure in the formation and maintenance of sister chromatid cohesion results in 
premature chromosome segregation, which is thought to be a major pathway to aneuploidy, a 
characteristic observed in many human cancers.107  
1.2.1.2 Cohesin functions in genome instability 
Cellular DNA is exposed to single and double strand breaks (DSBs) through multiple 
endogenous and exogenous mechanisms. Cells respond to DNA damage by activation of DNA-
damage checkpoints that halt cell cycle progression until the damaged DNA is repaired. If the 
damage cannot be repaired properly, cells may undergo apoptosis. Eukaryote cells have two 
distinct mechanisms to repair DSBs, the homologous recombination (HR) between sister 
chromatids in the S and G2 phases and the non-homologous end joining (NHEJ), involving re-
ligation of broken DNA, which occurs throughout the cell cycle.84  
The function of cohesin in DNA damage repair is evolutionarily conserved from yeast to 
humans.108, 109, 110 Rad21 was cloned originally by complementing the γ-radiation sensitivity in 
fission yeast with a function in DSB repair, before its role in sister chromatid cohesion was 
identified.111 In response to laser-induced DNA damage in human cells, cohesins are recruited to 
the DSB site and de novo cohesion, named damage-induced cohesion (DI-cohesion), is 
established.112 Besides cohesins, factors that are required to load cohesins to chromatin, establish 
cohesion, and maintain cohesion are all needed for DNA damage repair. Defects in the cohesin-
loading complex NIPBL-MAU2, cohesin acetyltransferase ESCO, or maintenance factor 
SORORIN block the accumulation of cohesins at DSBs and prevent DNA damage repair, 
suggesting the presence of cohesins on chromatin is not sufficient to mediate DNA repair and 
instead, additional cohesion is required.113, 114, 115 DI-cohesion may help to structurally stabilize 
chromosomes whose DNA backbone has been fragmented by DSBs and to provide the proximity 
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between the damaged sister chromatid and the template, allowing HR to occur. DNA damage-
induced phosphorylation and acetylation on SMC3 were found to be important for genome-wide 
DI-cohesion caused by DSB in the G2 phase and DSB repair.112  
Moreover, cohesins are required to activate checkpoints when DSBs occur.116 In C. elegans, 
when SCC2, a component of the cohesin loading complex, is mutated, cohesins cannot be loaded 
onto chromatin in meiosis, resulting in failure of both checkpoint activation and DNA damage 
repair.117 This shows the importance of cohesin recruitment to the damaged chromatin. The 
checkpoint role of cohesins is independent of its function in sister chromatid cohesion because 
cohesins are required for the phosphorylation and activation of Chk2 although no sister 
chromatid cohesion occurs in the G1 phase. As evidence, depletion of SORORIN, a protein 
essential for the generation and maintenance of sister chromatid cohesion, leads to checkpoint 
activation but DSB repair failure.116 
1.2.1.3 Cohesin functions in gene expression  
The first evidence that cohesin factors regulate gene expression and development came from the 
studies of Drosophila cut and Ultrabithorax genes: heterozygous Nipped-B mutants showed 
reduced cut expression, whereas loss of Smc1, Rad21, or SA led to increased cut expression.118, 
119 Cohesins also facilitate expression of c-myc, a function conserved across Drosophila, 
zebrafish, mouse, and humans and cohesin depletion reduces myc transcription.120 Furthermore, 
cohesins present in non-cycling and even post-mitotic cell in higher eukaryotes.121 Accumulating 
evidence implies an important non-canonical role of cohesin in regulating gene expression, 
which is independent of cohesins’ role in cell division.83 In non-dividing mouse thymocytes, 
genetic deletion of cohesin resulted in reduced transcription and rearrangements at the T cell 
receptor, thereby affecting thymocyte differentiation.122  
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Cohesins have been shown to mediate long-range transcriptional regulation by controlling the 
spatial conformation of chromatin at multiple gene loci that are important for normal 
development and differentiation.123 Studies revealed two distinct types of cohesin sites: sites that 
coincide with the binding of CTCF (CCCTC-binding factor) vs. sites that map to active 
enhancers and promoters and are usually cell-type specific. The CTCF-dependent interaction of 
cohesins with insulator blocks enhancer activity and disrupts distal enhancer-promoter 
interactions required for gene activation.121 Moreover, cohesin has a CTCF-independent role in 
tissue-specific transcriptional regulation.124 ChIP-Seq data suggest that cohesins co-localize with 
master regulators in several tissues, such as liver-specific transcription factors in HepG2 cells 
and estrogen receptor α in MCF-7 cells.124, 125 Cohesin also co-localize with transcriptional 
coactivators, such as mediator to facilitate chromatin looping between the enhancer and promoter 
of some pluripotency genes (e.g POU5F1) in mouse embryonic stem cells.126 The cohesin 
complex lacks a definitive DNA-binding domain. Therefore, DNA localization appears to be 
facilitated through binding to CTCF and transcription factors, thus forming a regulatory network 
for transcriptional programs of specific cell type.121 
Cohesins play an essential role in the maintenance of pluripotency. Depletion of cohesins blocks 
self-renewal, induces spontaneous differentiation, and interferes with reprogramming of 
fibroblasts to pluripotent cells.127 Mutations in core components of the cohesin complex can 
cause developmental defects in a number of species. For instance, heterozygous mutations in 
cohesin loader NIPBL or less frequently, in cohesin subunits SMC1A and SMC3 result in 
Cornelia de Lange syndrome (CdLS), a neurodevelopmental disorder with upper extremity 
malformations.90  
1.2.2 Cohesin deregulation in cancer 
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Mutations of cohesins have been found in many cancers including leukemias19, 49, 128, colorectal 
carcinomas129, ovarian carcinomas11, 130, glioblastoma, melanomas, and Ewing’s sarcomas131. 
The first somatic mutations of cohesin in cancer were reported in 2008 when heterozygous 
missense mutations in SMC1A, SMC3, STAG3 (a component of meiotic cohesin) and NIPBL 
were identified in aneuploid colorectal cancers.129 In 2010, deletions of RAD21 in a CML and 
deletions of STAG2 in an AML were reported.132 In 2011, STAG2 mutations were reported to 
result in cohesion defects and aneuploidy in glioblastoma cell lines, melanomas, and Ewing’s 
sarcomas.131 STAG2 is the most frequently mutated gene of the cohesin complex. Because 
STAG2 is located on the X chromosome, only a single mutational event is required to inactivate 
it in both males and females (due to X inactivation). STAG2 mutations are considered loss-of-
function mutations because: 1) the majority of mutations are truncating, 2) truncating mutations 
are present in early exons, resulting in a very short protein, 3) in many cases a truncated STAG2 
protein is absent, likely due to nonsense-mediated decay of the mutant STAG2 mRNA.133, 134 In 
2013, three studies reported frequent somatic mutations of STAG2 in bladder cancer.135, 136, 137 In 
addition, SMC1A has been shown to be overexpressed in gliomas and reducing its levels inhibits 
glioma cell growth in vitro.138 Upregulation of ESCO2 and WAPL is associated with tumor 
progression in melanomas and cervical cancer, respectively.139, 140 Overexpression of Separase is 
sufficient to induce tumorigenesis in mammary epithelial cells in a TP53-mutant background.141 
Pan-cancer analysis of the TCGA data found that the cohesin complex was recurrently mutated 
across 12 cancer types and identified the cohesin complex as one of the 16 significantly mutated 
subnetworks.142  
1.2.2.1 Cohesin mutations in myeloid malignancies 
Cohesin mutations in AML 
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Recurrent mutations in all four members of the cohesin complex, SMC1A, SMC3, RAD21, and 
STAG2 were first identified in M1 AML cases. They co-occurred with NPM1, RUNX1, 
DNMT3A, or TET2 mutations in 17/19 cases, indicating cooperation with other leukemogenic 
pathways.49 Subsequently, the TCGA data confirmed and extended these results, identifying a 
cumulative cohesin mutation frequency of 13% (26/200).11 The frequency of cohesin mutations 
was assessed in both de novo and secondary AML. One study showed a higher frequency of 
cohesin mutations in de novo AML (13%, 16/120 samples studied) than in secondary AML (8%, 
3/37 samples studied).77 In contrast, another study showed a higher frequency of cohesin 
mutations in secondary AML (20%, 30/149) than in de novo AML (11%, 32/301).78 In both 
studies, the most frequently mutated cohesin gene was STAG2, followed by SMC3 and RAD21.77, 
78 Cohesin mutations are nearly always mutually exclusive and are mostly found in samples with 
normal karyotypes. Based on allelic burden analysis, cohesin mutations are often, but not always, 
observed as early event during leukemogenesis.76  
Cohesin mutations in MDS 
STAG2 mutations were identified in MDS samples from patients whose disease later progressed 
to secondary AML.143 Subsequent studies showed that 7% (10/150) of MDS samples harbor 
STAG2 mutations and 8% (18/224) of MDS samples harbor cohesin mutations, the majority of 
which were STAG2 mutations, with lower mutation frequencies in SMC3 and RAD21.77, 144 
Cohesin mutations were also identified in 17% of high-risk MDS samples and 11% of low-risk 
samples, respectively.78 
Cohesin mutations in DS-AMKL 
Down syndrome is associated with trisomy 21, and individuals with trisomy 21 are more 
susceptible to hematologic abnormalities. Up to 10% of children with Down syndrome will 
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present with transient abnormal myelopoiesis at birth, a necessary predecessor to DS-AMKL. 
Virtually all DS-AMKL patients have an inactivating mutation in GATA1, which results in 
exclusive expression of a shorter isoform, named GATA1s.80  
Cohesin mutations are prominent in DS-AMKL and are predicted to be heterozygous, loss-of-
function, and early events during leukemia development. Deep sequencing revealed that 53% of 
the DS-AMKL samples had acquired cohesin mutations that were not in the self-limiting pre-
leukemic transient abnormal myelopoiesis, suggesting cohesin haploinsufficiency may drive 
oncogenic transformation and progression to DS-AMKL.79 In addition to the presence of trisomy 
21 and GATA1s, cohesin mutations likely cooperate with chromosome 21 genes such as 
RUNX1, ERG, and ETS2 to promote the development of DS-AMKL.80, 145 Furthermore, 
mutations in CTCF occur in approximately 20% of DS-AMKL and are not mutually exclusive to 
cohesin mutations.80 Cohesins and CTCF interact to regulate chromatin architecture, and thus 
mutations in either could have non-overlapping effects on genomic structure and induce global 
changes on gene expression.  
Phenotypic consequences of cohesin mutations on hematopoiesis 
Four recent studies sought to elucidate the phenotypic consequences of loss of cohesin and 
cohesin mutations on hematopoiesis in mouse and human models (Table 1.2146).147, 148, 149, 150  
Viny et al. showed a dose-dependent role for Smc3 in regulating hematopoietic stem and 
progenitor cell (HSPC) function and chromatin structure. Biallelic loss of Smc3 in mice led to 
bone marrow aplasia with premature sister chromatid separation, revealing an absolute 
requirement for cohesin in HSPC function; whereas, Smc3 haploinsufficiency increased self-
renewal in vitro and in vivo. Furthermore, Smc3 haploinsufficiency reduced expression of 
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transcription factors and lineage commitment-associated genes and cooperated with FLT3-ITD 
mutation to induce AML in vivo.147  
Mullenders et al. generated a series of inducible shRNA mouse models targeting each of the four 
cohesin subunits. Knockdown of cohesin resulted in gain of replating capacity of mouse HSPCs 
and altered hematopoiesis with skewing towards myeloid differentiation. Upregulation of genes 
involved in myeloid differentiation and increased chromatin accessibility around those genes 
were also observed. In addition, aged cohesin knockdown mice developed a clinical picture 
closely resembling MPNs, implying that cohesin mutations can occur as an early event in 
leukemogenesis and facilitate the potential development of a myeloid malignancy.148  
Complementary work in cohesin mutant human HSPCs showed that depletion of cohesin 
subunits increased replating capacity in vitro and led to myeloid-skewed differentiation, 
consistent with phenotypes seen in mouse models. Mazumdar et al. found that introduction of 
cohesin mutants into AML cell lines and primary human cord blood HSPCs resulted in a 
differentiation block with an increased frequency of CD34+ cord blood progenitors. Cohesin 
mutants augmented the serial replating capability of human HSPCs in vitro and elevated 
chromatin accessibility and predicted transcription factor binding for HSPC regulators including 
RUNX1, GATA2, and ERG, measured by ATAC-Seq and ChIP-Seq.149  
Similarly, Galeev et al. identified several members of the cohesin complex SMC3, RAD21, 
STAG1/2 in an RNAi screen as critical modifiers of self-renewal and differentiation in human 
HSPCs. They showed that cohesin deficiency induced HSC-specific gene programs and the 
reconstitution potential of cohesin-deficient HSPCs was increased in primary and secondary 
transplantation studies.150   
 
25 
 
Figure Legends 
Figure 1.1. Eight functional categories of genes that are frequently mutated in AML.17  
Mutations in signaling genes such as FLT3 (upper left box). Mutations in tumor-suppressor 
genes such as TP53 (upper middle box). Mutations in DNA-methylation-associated genes such 
as DNMT3A, TET2, IDH1, and IDH2 (upper right box). Mutations in myeloid transcription 
factors such as RUNX1 (center left box). Mutations in cohesin-complex genes such as STAG2 
and RAD21 (center middle box). Mutations in chromatin-modifying genes such as ASXL1 and 
PHF6 (center right box). Mutations in NPM1 (lower left box). Mutations in spliceosome-
complex genes such as SRSF2, SF3B1, U2AF1, and ZRSR2 (lower right box).  
Figure 1.2. The cohesin complex.86 
Cohesin is a ring-shaped complex, composed of four core subunits SMC1A, SMC3, RAD21, and 
STAG1/2. SMC1A and SMC3 form intramolecular antiparallel coiled coils and fold back on 
themselves, creating a hinge domain at one end and an ATPase head at the other. SMC1A and 
SMC3 dimerize at the hinge domains and their ATPase heads are bound by RAD21. STAG1/2 
interacts with the central region of RAD21. PDS5, SORORIN, and WAPL are regulatory 
proteins of cohesin.  
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Figure 1.1. Eight functional categories of genes that are frequently mutated in AML.17  
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Figure 1.2. The cohesin complex.86 
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Table 1.1. Core subunits and regulatory proteins of the cohesin complex.84  
Mammals D. melanogaster S. cerevisiae S. pombe Function 
SMC1A 
Smc1 Smc1 Psm1  
Core subunit (mitosis) 
SMC1B Core subunit (meiosis) 
SMC3 Smc3 Smc3 Psm3 Core subunit 
RAD21 Rad21/Vtd Scc1/Mcd1 Rad21 Core subunit (mitosis) 
REC8 C(2)M Rec8 Rec8 Core subunit (meiosis) 
STAG1/SA1 SA 
Scc3 
Psc3 
Core subunit (mitosis) 
STAG2/SA2 SA2 Core subunit (mitosis) 
STAG3/SA3 / Rec11 Core subunit (meiosis) 
NIPBL/SCC2 Nipped-B Scc2 Mis4 Cohesin loading 
MAU2/SCC4 Scc4 Scc4 Ssl3 Cohesin loading 
ESCO1 Eco/Deco 
Eco1/Ctf7 Eso1 Cohesion establishment 
ESCO2 San 
PDS5A 
Pds5 Pds5 Pds5 Cohesion maintenance 
PDS5B 
WAPL Wapl Wpl1/Rad61 Wpl1 Cohesion maintenance 
SORORIN/CDCA5 Dalmatian / / Cohesion maintenance 
HDAC8 / Hos1 / Cohesin dacetylase 
Shugosin1/SGOL1 Mei-S332 Sgo1 Sgo1 Cohesin protection 
Separase Sse1 Esp1 Separase Cohesin removal 
Polo like Kinase 1 
(PLK1) 
Polo Cdc5 Plk1 Cohesin removal 
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Table 1.2. Studies of cohesin mutations in hematopoiesis.146  
Model system Approach Conclusions 
Mouse model 
Smc3biallelic and 
haploinsufficient 
conditional 
knockout 
Increased replating, enrichment of HSPC 
gene signature, chromatiin accessibiligy 
changes, dose dependent 
Mouse model 
shRNA 
knockdown of 
cohesin subunits 
Increased replating, enrichment of HSPC 
gene signature, chromatiin accessibiligy 
changes, MPN-like phenotype in aged mice 
Human cord blood 
(HSPCs) 
Lentiviral 
transduction of 
cohesin mutants or 
shRNA 
knockdown 
Increased replating, enrichment of HSPC 
gene signature, chromatiin accessibiligy 
changes 
Human cord blood 
(HSPCs) 
RNAi screen 
Increased replating, enrichment of HSPC 
gene signature, increased secondary transplant 
engraftment 
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Abstract  
SMC3 encodes a subunit of the cohesin complex that has canonical roles in regulating sister 
chromatids segregation during mitosis and meiosis. Recurrent heterozygous mutations in SMC3 
have been reported in acute myeloid leukemia (AML) and other myeloid malignancies. In this 
study, we investigated whether the missense mutations in SMC3 might have dominant-negative 
effects or phenocopy loss-of-function effects by comparing the consequences of Smc3 deficient 
and haploinsufficient mouse models. We found that homozygous deletion of Smc3 during 
embryogenesis or in adult mice led to hematopoietic failure, suggesting that SMC3 missense 
mutations are unlikely to be associated with simple dominant negative phenotypes. In contrast, 
Smc3 haploinsufficiency was tolerated during embryonic and adult hematopoiesis. Under steady-
state conditions, Smc3 haploinsufficiency did not alter colony forming in methylcellulose, only 
modestly decreased mature myeloid cell populations, and led to limited expression changes and 
chromatin alteration in Lin-cKit+ bone marrow cells. However, following transplantation, 
engraftment, and subsequent deletion, we observed a hematopoietic competitive disadvantage 
across myeloid and lymphoid lineages and within the stem/progenitor compartments. This 
disadvantage was not affected by hematopoietic stresses but was partially abrogated by 
concurrent Dnmt3a haploinsufficiency, suggesting that antecedent mutations may be required to 
optimize the leukemogenic potential of Smc3 mutations.  
Introduction 
Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy, characterized by the 
accumulation of myeloblasts in the blood or bone marrow (BM) with maturation arrest and 
retained self-renewal.1 Tremendous progress has been made in identifying recurrent gene 
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mutations in AML, yet we are still in the early stages of understanding the mechanisms through 
which these genetic alterations contribute to the onset of the disease.2  
Recurring mutations in the cohesin complex occur in four core components, SMC3, SMC1A, 
RAD21, and STAG2, and have been identified in AML and other myeloid malignancies.3, 4, 5 Over 
50% of patients with Down syndrome-associated acute megakaryocytic leukemia (DS-AMKL) 
have cohesin mutations, specifically in STAG2.6 Somatic cohesin mutations have also been 
observed in a variety of solid cancers, including colorectal carcinoma, ovarian carcinoma, 
glioblastoma, bladder carcinoma, and Ewing’s sarcoma.7, 8, 9, 10, 11, 12 Additionally, germline 
mutations of the cohesin complex are causally related to developmental disorders, particularly 
cohesinopathies such as Cornelia de Lange syndrome (CdLS).13, 14 
SMC3 and RAD21 mutations are nearly universally heterozygous, whereas mutations in SMC1A 
and STAG2 may be hemizygous because they are X-linked. Cohesin mutations also tend to be 
mutually exclusive, implying that alteration in one component may be sufficient to disrupt the 
entire complex or alternatively, they may not be tolerated by a cell when co-occurring.15, 16 
Cohesin mutations are often observed as early subclonal events in AML, conceivably facilitating 
disease initiation, although they are not observed in cases of clonal hematopoiesis of 
indeterminate potential (CHIP), suggesting they are unlikely to be the initiating event.15, 17, 18, 19  
The majority of SMC3 mutations are missense mutations; only one-third of SMC3 mutations are 
nonsense or splice-site variants. The missense mutations are scattered across all domains, 
although a few recurrently mutated nucleotides have been observed (R381Q, R661P). This 
pattern suggests that many of these mutations may result in simple loss-of-function 
consequences, although novel dominant negative activities cannot be dismissed within the hot-
spot variants. Intriguingly, DNMT3A mutations, one of the most commonly mutated genes in 
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AML, frequently coincided with SMC3 mutations, suggesting there may be leukemogenic 
interactions between these mutations.5, 15, 16, 20 
In yeast and cell line-based studies, cohesin has been shown to play essential roles in sister 
chromatid segregation during cell cycle, DNA damage repair, transcriptional regulation via 
chromatin looping, and maintenance of chromatin architecture.21, 22, 23, 24 Notably, AML patients 
who harbor cohesin mutations typically have normal karyotype, indicating that hematopoietic 
cohesin mutations do not lead directly to chromosomal instability.25, 16  
To define the hematopoietic consequences of SMC3 mutations and to determine whether these 
could reflect dominant negative or loss of function phenotypes, we characterized the in vivo 
effects of Smc3 deficiency and Smc3 haploinsufficiency on murine hematopoiesis using 
conditionally deleted strategies. In contrast to our expectations that these leukemia-associated 
mutations would lead to expansions of hematopoietic stem cell populations or augmented self-
renewal, we observed a competitive disadvantage in Smc3 deficient and haploinsufficient BM 
cells in vivo without an associated increase in maturation-arrested stem cells.  
Methods 
Animal Studies 
Smc3trap mice were obtained from the European Conditional Mouse Mutagenesis Program 
(EUCOMM) (Smc3<tm1a(EUCOMM)Wtsi>, MGI:4434007). To generate Smc3fl mice, the 
gene-trap was removed by crossing Smc3trap mice with Flp deleter mice (B6.129S4-
Gt(ROSA)26Sortm2(FLP*)Sor/J), and subsequently outbreeding the Flp allele with C57BL/6J 
intercrosses. We generated Smc3 conditional deficient mice by breeding the Smc3fl/fl mice with 
Vav1-Cre (B6.Cg-Commd10Tg(Vav1-icre)A2Kio/J), ERT2-Cre (B6.Cg-Tg(cre/Esr1)5Amc/J), 
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and CMV-Cre (B6.C-Tg(CMV-cre)1Cgn/J), obtained from the Jackson Laboratory. We 
characterized Smc3 conditional deficient mice at 6-8 weeks old and both genders were used. 
Whenever possible, littermate controls were used for all experiments. CBCs were measured 
using Hemavet 950 (Drew Scientific Group). 
All mice were on the C57BL/6 background and were cared for in the Experimental Animal 
Center of Washington University School of Medicine. The Washington University Animal 
Studies Committee approved all animal experiments. 
Intracellular Smc3 staining 
Intracellular Smc3 was detected with the Pharmingen™ Transcription Factor Buffer Set (562574 
BD Biosciences) according to the manufacturer’s instructions. BM cells were isolated from 
femurs and tibias and lysed with ACK lysis buffer (150mM NH4Cl, 10mM KHCO3, 0.1mM 
Na2EDTA [Na2-ethylenediaminetetraacetic acid], PH7.2-7.4). Cells were stained with cell-
surface markers to identify cell type by flow cytometry and then fixed for 40 minutes at 4°C. 
Cells were washed with perm wash buffer and incubated with primary antibody against Smc3 
(1:100 dilution, ab9263, Abcam) for 30 minutes at 4°C. Cells were washed in perm wash buffer 
and incubated in secondary antibody (1:500 dilution, chicken anti-rabbit Alexa Fluor 647, 
Molecular Probes) for 30 minutes at 4°C. Cells were rinsed in perm wash buffer and analyzed by 
flow cytometry. The mean fluorescence intensity was calculated for the AF647 signal.  
Flow cytometry 
After lysis of red blood cells by ACK lysis buffer, peripheral blood, BM, spleen cells, or 
thymocytes were treated with anti-mouse CD16/32 (eBioscience; clone 93) and stained with the 
indicated combinations of the following antibodies (all antibodies are from eBioscience unless 
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noted otherwise): CD34 FITC (clone RAM34), CD11b PE (clone M1/70), c-Kit PECy7 (clone 
2B8) or BV421 (BioLegend, clone 2B8), Sca1 PE-Dazzle™ 594 (BioLegend, clone D7) or APC 
(clone D7), Gr-1 FITC, PECy7, APC (clone RB6-8C5), or BV421 (BioLegend, clone RB6-8C5), 
B220 PE, PECy7, APC (clone RA3-6B2), or APC-Cy7 (BioLegend, clone RA3-6B2), CD3 
PECy7 (clone 145-2C11), CD71 PE(clone R17217), Ter-119 PECy7 or APC (clone TER-119), 
CD16/32 BV510 (clone 93), CD150 PE (BioLegend 115903, clone TC15-12F12.2), CD48 APC-
Cy7 (BioLegend, clone HM48-1), Ly5.1 APC (clone A20) or AF700 (BioLegend, clone A20), 
Ly 5.2 PE or e450 (clone 104). The following flow phenotypes were used for stem and 
progenitor cell flow: Lin- (lineage negative): B220-, CD3e-, Gr-1-, Ter-119-, CD4-, CD8-, 
CD19-, CD127-; KL: Lin-, cKit+, Sca1-; KLS: Lin-, cKit+, Sca-1+; KLS-SLAM: Lin-, cKit+, 
Sca-1+, CD150+, CD48-; GMP: Lin-, cKit+, Sca-1-, CD34+, CD16/32+; CMP: Lin-, cKit+, Sca-
1-, CD34+, CD16/32-; and MEP: Lin-, cKit+, Sca-1-, CD34-, CD16/32-. 
Analysis was performed using a FACScan (Beckman Coulter) or Gallios flow cytometer 
(Beckman Coulter). Cell sorting was performed using I-Cyt Synergy II sorter (I-Cyt 
Technologies). Flow cytometry data were analyzed with FlowJo Software Version 10 (TreeStar), 
Excel (Microsoft), and Prism 7.02 (GraphPad Software).  
Competitive transplantation 
Competitive transplantation was performed using 0.5 x 106 whole BM cells from indicated donor 
mice (CD45.2) mixed with 0.5 x 106 competitor whole BM cells wild-type CD45.1 (Ly5.1) x 
CD45.2 mice. Mixture cells were injected intravenously into 6-8 weeks old CD45.1 recipient 
mice that received 1,100 cGy total body irradiation (Mark 1 Cesum irradiator, J.L. Shepard) 24 
hours prior to transplantation. For Smc3fl/fl/ERT2-Cre+/- or Smc3fl/+/ERT2-Cre+/- transplantation, 
recipient mice were treated with tamoxifen (dissolved in sterile corn oil, Sigma-Aldrich) 6 weeks 
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post-transplant via oral gavage for 9 doses (3 mg/day/mouse, 3 days/week). Peripheral blood was 
examined for donor cell chimerism at indicated time points after transplantation. Recipient mice 
BM were analyzed at the end of experiment. 
Colony replating assay 
BM cells were harvested and plated in duplicate (10,000 BM cells/plate) in complete mouse 
methylcellulose medium with stem cell factor, IL-3, IL-6, and Epo (R&D Systems). Colonies 
were counted on day 7, and cells were collected from methylcellulose in warm Dulbecco 
modified Eagle medium containing 2% fetal bovine serum, washed, and replated as before. An 
aliquot of cells was taken for analysis of myeloid (Gr1, CD11b) and mast cell markers (cKit, 
FcER1) by flow cytometry. This process was repeated for 4 weeks or until colony formation 
failed.  
RNA sequencing of multipotent progenitors and analysis 
Multipotent progenitors (KLs; Lin-, cKit+, Sca1-) were sorted from three wild-type or 
Smc3fl/+/Vav1-Cre+/- mice into DMEM media. Flow cytometry of samples after sorting 
validated >93% sort accuracy. RNA was extracted from cell pellets using a miRNeasy kit 
(QIAGEN) and genomic DNA was removed by RNase-Free DNase Set (QIAGEN). RNA was 
analyzed for degradation using the RNA Nano Chip (Agilent #5067-1521). An input of 300ng 
was taken forward for each sample using the TruSeq Stranded Total RNA with Ribo-Zero 
Globin Kit (Ilumina #20020612). Final Libraries were analyzed using the High Sensitivity DNA 
Chip (Agilent# 5067-4626). All Libraries were pooled and run across 3 lanes of HiSeq4000. 
RNAseq data were aligned to the human reference with Tophat v2.0.8 (denovo mode, params: --
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library-type fr-firststrand --bowtie-version=2.1.0). Expression levels were calculated with 
Cufflinks v2.1.1 (params: --max-bundle-length 10000000 --max-bundle-frags 10000000).52 
ATAC-Sequencing of multipotent progenitor and analysis 
Chromatin accessibility assays using the bacterial Tn5 transposase were performed using 
multipotent progenitors (KLs; Lin-, cKit+, Sca1-) sorted from Smc3fl/+ or Smc3fl/+/Vav1-Cre+/- 
mice in triplicate. DNA was prepared from 75,000 sorted cells and >93% sorting accuracy 
verified with post-sort analysis. ATAC libraries were generated exactly as described53 and 
pooled and sequenced on a HiSeqX instrument (Illumina) to obtain between 133 and 152 million 
2x150 bp paired-end reads. Raw sequencing reads were adapter trimmed with trim galore using 
cutadapt version 1.8.1 (Martin EMBnet 2011) and then aligned to the mouse reference genome 
(mm10) using bwa mem (Li H. arXiv:1303.3997v1 (2013)). Peaks in each sample were 
identified with macs254 using the -f BAMPE parameter and then filtered to retain peaks with a q-
value <0.01. Peak summits from all samples were merged together with BEDtools merge55 using 
parameters to combine summits within 50 bp of each other. Read counts at the merged peak 
summits were obtained for all samples using the deepTools multiBamSummary command56 with 
the minimum mapping quality set to 1, and then processed using DESeq257 with default 
parameters to obtain normalized counts for each peak summit and to perform differential 
analysis across all peaks between wild-type and mutant mice. 
Statistics 
Statistical analysis was performed using Prism 7.02 (GraphPad Software) and Excel (Microsoft). 
Unpaired two-tailed t-test, one-way, and two-way ANOVA with Turkey’s multiple comparisons 
tests were performed, as appropriate. P values < 0.05 were considered statistically significant. 
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Error bars represent standard deviation. Data points without error bars have standard deviation 
below Prism 7.02’s limit to display. 
Results 
Generation of Smc3 conditional knockout mice 
To investigate the effects of Smc3 loss on hematopoiesis, we generated Smc3 conditionally 
deficient and haploinsufficient mice using Smc3<tm1a(EUCOMM)Wtsi> mice obtained from 
EUCOMM (Smc3trap). The Smc3trap allele has a lacZ-neomycin-gene-trap cassette inserted in 
intron 4 with two Frt sites on each side of the cassette, and two loxP sites flanking exon 4. The 
gene trap is predicted to lead to an early transcription stop after splicing into lacZ-neomycin. The 
conditional knockout Smc3fl allele was created by excising the gene-trap cassette with Flp 
recombinase and was used for further characterizations because homozygous deletion could be 
achieved using the Smc3fl allele (Figure 2.1A). We validated the integration of the loxP sites 
surrounding exon 4 in the Smc3fl allele using whole genome sequencing (Figure 2.1B). 
We examined the transcriptional consequences of the Smc3fl allele using RNA-Seq and 
intracellular flow cytometry. In BM cells from three Smc3fl/+/Vav1-Cre+/- mice, nearly 50% 
(48.4%) of transcripts spliced from exon 3 to exon 5, consistent with deletion of exon 4 while all 
the wild-type transcripts spliced from exon 3 to exon 4 and exon 4 to exon 5 (Figure 2.1C and 
Figure 2.7A-F). Analysis of reads spanning exons 3-5 suggests that this results in a frameshift 
mutation and a stop codon after 59 amino acids, although this truncated protein could not be 
detected using N-terminal antibodies. Using C-terminal antibodies, intracellular Smc3 protein 
level was reduced to approximately half of littermate control, as would be expected with a 
heterozygous allele and confirming Smc3 haploinsufficiency (Figure 2.1D). In addition, we noted 
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that Smc3 protein level was regulated during normal hematopoiesis, with higher expression in 
KLS (Lin-cKit+Sca1+) stem/progenitor cells vs. SLAM (Lin-cKit+Sca1+CD150+CD48-) stem 
cells (Figure 2.1E). Representative primary intracellular flow data shown in Figure 2.8.  
Homozygous Smc3 deletion  
To understand whether SMC3 mutations might have dominant-negative effects or phenocopy 
loss-of-function effects, we compared the consequences of Smc3 deficient and haploinsufficient 
mouse models. We found that hematopoietic homozygous deletion of Smc3 led to embryonic 
lethality. In heterozygous Smc3fl/+/Vav1-Cre+/- intercrosses, we observed 0 out of 75 pups with 
homozygous Smc3 alleles (Figure 2.2A). To determine whether the cause of death in 
Smc3fl/fl/Vav1-Cre+/- embryos was from hematopoietic failure, we examined E13.5 embryos. 
Grossly, the Smc3fl/fl/Vav1-Cre+/- embryos were indistinguishable in size and appearance from 
other genotypes, except the lack of obvious fetal livers (Figure 2.2B-C). A severe decrease in 
fetal liver hematopoietic cells was verified by cell count and flow cytometry with near-complete 
absence of CD45+ Gr1+ CD11b+ cells demonstrating myeloid-biased hematopoietic failure 
(Figure 2.2D-F).  
We investigated somatic homozygous Smc3 deletion in adult mice using the Smc3fl/fl/ERT2-
Cre+/- mice. Smc3 deletion was achieved by treating mice with oral tamoxifen (TAM) at 6 weeks 
of age and reduction in Smc3 protein confirmed with western blot (Figure 2.9A). After 4 doses 
of TAM, mice were moribund and therefore sacrificed for analysis. Complete blood counts 
(CBC) data showed the Smc3fl/fl/ERT2-Cre+/- mice had lower white blood cell counts, 
percentages of lymphocytes and monocytes, and fewer platelets than TAM-treated littermates 
(Figure 2.3A). The Smc3fl/fl/ERT2-Cre+/- mice had decreased spleen weights (Figure 2.3B) and 
their spleens were smaller in size (Figure 2.9B). Total number of cells in BM, spleen, and 
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thymus of the Smc3fl/fl/ERT2-Cre+/- mice were significantly reduced in comparison to Smc3fl/fl 
mice after TAM treatment (Figure 2.3C). The reduction of cells occurred across all lineages in 
the BM (Figure 2.3D), spleen, and thymus (Figure 2.9C-D) of the Smc3fl/fl/ERT2-Cre+/- mice, 
suggesting complete hematopoietic collapse.  
Because activation of ERT2-Cre leads to Smc3 deletion in a wide range of cells and tissues, we 
repeated these studies, isolating hematopoietic cells via a competitive transplantation. Equivalent 
engraftment of transgenic CD45.2+ and competitor CD45.1+ CD45.2+ cells was verified 6 
weeks after transplantation. Following tamoxifen-induced Smc3 deletion, the Smc3fl/fl/ERT2-
Cre+/- donor cells were quickly outcompeted, indicating complete loss of hematopoietic stem and 
progenitor cell (HSPC) functions in the Smc3fl/fl/ERT2-Cre+/- BM. Once again, the effect was 
most pronounced within the myeloid compartment (Figure 2.3E-F), suggesting that myeloid 
hematopoiesis is sensitive to Smc3 deletion and therefore, the AML-associated SMC3 mutations 
are unlikely to have simple dominant-negative effects.  
Steady-state heterozygous Smc3 deletion  
In the ExAC database (exac.broadinstitute.org), no SMC3 loss-of-function mutations are 
observed in available human data (0 observed vs. 58.5 expected mutations), suggesting potential 
embryonic lethality or reduced fitness associated with Smc3 haploinsufficiency. We, therefore, 
determined whether Smc3 haploinsufficiency might be tolerated in mice. Because CMV-Cre is 
X-linked and expressed during early embryogenesis, we examined the ratio of male: female pups 
and compared difference between genders to determine whether embryonic Smc3 
haploinsufficiency altered hematopoiesis. We found that Smc3 haploinsufficiency led to a normal 
number of female pups in CMV-Cre intercrosses (Figure 2.10A), and the female pups had no 
obvious defects in complete blood counts, total number of BM cells, and percentages of HSPCs 
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and cells in different lineages (Figure 2.10B-E). Hence, embryonic Smc3 haploinsufficiency 
could be tolerated and did not grossly perturb steady-state hematopoiesis in mice.  
We next assessed the effects of somatic Smc3 haploinsufficiency on hematopoiesis using the 
inducible Smc3fl/+/ERT2-Cre+/- mice. Smc3 haploinsufficiency did not alter the proportions of 
immunophenotypic HSPCs and cells of different lineages (Figure 2.4A-B).  
Furthermore, Smc3 haploinsufficiency did not increase the number of colonies formed in 
methylcellulose or the average number of cells per colony, and the Smc3 haploinsufficient BM 
cells did not replate beyond two weeks (Figure 2.4C-E). At the end of each week, the colonies on 
each plate were collected, washed, and characterized by immunophenotype. At the end of week 
1, the cells were predominantly Gr1+ CD11b+ for both Smc3fl/+/ERT2-Cre+/- and Smc3fl/+ 
genotypes. However, starting week 2, the colonies shifted to cKit+ FcER1+ mast cells. In week 3 
and 4, the few colonies left were exclusively mast cells (Figure 2.11A-B). Similar results were 
observed using BM cells from Smc3fl/+/Vav1-Cre+/- mice. 
We performed RNA-Sequencing to measure global gene expression in Smc3 haploinsufficient 
hematopoietic progenitors (Lin-cKit+Sca1-) using the constitutive Smc3fl/+/Vav1-Cre+/- model. 
This model was chosen because it required minimal manipulation of the mice, provided 
hematopoietic-restricted deletion, and would evaluate steady-state hematopoietic conditions. 
Multipotent progenitors (KLs) were sorted from age-matched individual wild-type and 
Smc3fl/+/Vav1-Cre+/ mice for RNA-Seq. KLs were selected because Smc3 haploinsufficiency 
resulted in severe multi-lineage competitive disadvantage in vivo, suggesting potential defect in 
the functions of Smc3 haploinsufficient KLs. However, minimal global transcriptional changes 
were detected. Using t-tests and Significance Analysis of Microarrays (SAM)26 149 genes were 
identified with differential expression in Smc3 haploinsufficient KLs in comparison to wild-type 
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controls (most with < 2 fold changes) (Figure 2.4F). KEGG pathway analysis showed 
significance (p<0.002 and p<0.005) for progesterone mediate oocyte maturation and 
toxoplasmosis respectively, but these are not related to hematopoiesis.27 Smc3 expression was 
not observed to be different when analyzed using total reads across the entire gene. However, we 
observed a two-fold reduction in expression of exon 4 consistent with deletion of this exon 
(Figure 2.1C). 
To determine whether Smc3 haploinsufficiency might lead to alterations in global chromatin 
structure that may be biologically relevant, but which did not lead to measurable altered gene 
transcription, we performed transposase-accessible chromatin sequencing (ATAC-Seq). 
Chromatin accessibility peaks of the Smc3fl/+/Vav1-Cre+/ KLs and littermate Smc3fl/+controls 
revealed by ATAC-Seq were not significantly different except for peaks in proximity of three 
genes: Vav1, Tnpo3, Tgfb (Figure 2.4G). The two-fold difference in Vav1 was expected for the 
heterozygous allele and therefore indicated fidelity of data generated by the assay. 
Phenotypes of Smc3 haploinsufficiency following competitive transplantations 
AML emerges following clonal expansion. Thus, we conducted competitive transplantation 
using the inducible ERT2-Cre model instead of the constituent hematopoietic Vav1-Cre, so that 
complete engraftment could be verified 6 weeks after transplant prior to deletion of the Smc3 
allele. In competitive transplantations, we observed a significant competitive disadvantage in the 
Smc3fl/+/ERT2-Cre+/- BM cells (Figure 2.5A). Endpoint analysis of BM cells also showed 
competitive disadvantage in the Smc3fl/+/ERT2-Cre+/- HSPCs and across B and T-cell lineages, 
implying impaired HSPC functions due to Smc3 haploinsufficiency in the BM, and not a defect 
in hematopoietic peripheralization or maturation (Figure 2.5B-F). The competitive disadvantage 
was observed first in the Gr1 myeloid compartment, perhaps due to higher turn-over of these 
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cells (Figure 2.5D). To verify the competitive disadvantage observed was not due to toxicity of 
ERT2-Cre, we repeated the competitive transplantation with the ERT2-Cre+/- control mice. The 
chimerisms of overall CD45.2+ cells and of CD45.2+ cells in all lineages were well-preserved, 
eliminating the possibility of ERT2-Cre toxicity (Figure 2.12A-B). 
The absence of pre-leukemic delayed maturation or augmented self-renewal in Smc3 
haploinsufficient mice was unexpected. Hence, we determined whether Smc3 haploinsufficiency 
might increase self-renewal if it occurred in combination with specific conditions of 
hematopoietic stress. We again observed a competitive disadvantage in the Smc3fl/+/ERT2-Cre+/- 
BM cells following tamoxifen induction. Intriguingly, the significant myeloid competitive 
disadvantage was ameliorated at 18 weeks post-transplantation in the pIpC-treated group, 
whereas it was accelerated in the 5-fluorouracil (5-FU) treated group, although this effect was 
transient and by week 26 the donor cell population were equivalently reduced (Figure 2.5G-J).  
Dnmt3a haploinsufficiency partially abrogated myeloid competitive disadvantage in Smc3 
haploinsufficient BM cells 
In AML patients, DNMT3A mutations co-occurred in approximately one-third of the cases with 
SMC3 mutations that assess additional mutations.4, 5, 15, 16 We therefore asked whether Smc3 
haploinsufficiency might lead to a competitive advantage if it occurred in the background of 
Dnmt3a haploinsufficiency20.  
We observed that with the addition of Dnmt3a haploinsufficiency, the severe competitive 
disadvantage was partially abrogated in the Smc3fl/+/ERT2-Cre+/- myeloid cells, but the 
significant competitive disadvantage in other lineages remained intact (Figure 2.6A-D). The 
same phenotype was observed in the Smc3fl/+/ERT2-Cre+/-/Dnmt3a+/- BM upon endpoint analysis 
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(Figure 2.6E). Accordingly, even with constitutive Dnmt3a haploinsufficiency, Smc3 
haploinsufficiency did not result in competitive growth advantage in hematopoietic cells. 
Discussion 
AML is a genetically heterogenous disease characterized by clonal expansion of immature 
myeloblasts. associated with recurrent mutations including the cohesin complex.25, 4, 5, 15, 16, 28 
Mutations in the subunits of the cohesin complex, SMC1A, SMC3, RAD21, and STAG2, have 
been found as early subclonal events in AML, although they are not observed in people with 
CHIP.5, 15, 16, 18, 19 In contrast, DNMT3A mutations are among the most common initiating 
mutations in normal karyotype AML patients and the most frequently mutated genes in subjects 
with CHIP.25, 29 Cohesin mutations are mutually exclusive of one another and fall into two 
general categories: mutations in RAD21 and STAG2 are mainly truncations and frameshifts, 
whereas the majority of mutations in SMC1A and SMC3 are missense. In AML, cohesin 
mutations are not associated with genomic instability, complex karyotypes, or monosomy 
karyotypes, suggesting alternative pathologic mechanisms.4, 5, 15 
To understand whether leukemia-associated SMC3 missense mutations might have dominant-
negative activities or phenocopy loss-of-function effects, we compared the consequences of 
Smc3 deficiency and Smc3 haploinsufficiency on murine hematopoiesis using conditionally 
deleted strategies. We began by validating the Smc3 allele using whole genome sequencing, 
RNA-Seq, and intracellular flow cytometry, which demonstrated correct integration, splicing of 
approximately 50% of alleles around exon 4 leading to a frameshift mutation and an early 
nonsense mutation, and reduced protein levels. Our findings suggest that leukemia-associated 
SMC3 mutations are unlikely to have novel dominant negative activities because homozygous 
Smc3 deletion was incompatible with embryonic (Figure 2.2) or adult hematopoiesis (Figure 
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2.3). In these experiments, we observed the effects first in the myeloid compartment. However, 
because myeloid cells have a shorter half-life than other hematopoietic cell types, the augmented 
temporal phenotypes observed in these cell fractions may be influenced by greater turn-over. 
Collectively, these studies demonstrate that Smc3 is indispensable for embryonic and adult 
hematopoiesis and normal HSPC functions. Similar severe consequences for Smc3 deficiency30 
and Rad21 deficiency31 have been observed, and thus cohesin genes appear to be essential in 
hematopoietic cells.  
Leukemia-associated SMC3 mutations are observed across all domains of the protein, and nearly 
one third are nonsense or splice-site variants, suggesting that many of these mutations are likely 
to be associated with loss of function. Therefore, we investigated the effects of Smc3 
haploinsufficiency on murine hematopoiesis. Because these mutations are associated with 
leukemia, we predicted that Smc3 haploinsufficiency would augment colony forming capacity 
and provide hematopoietic cells a competitive advantage. However, we observed neither 
phenotype. Following Smc3 haploinsufficiency induced with three different Cre models (CMV-
Cre, Vav1-Cre, and ERT2-Cre) we observed normal CBCs, normal bone marrow hematopoietic 
population distributions, and normal colony forming (Figure 2.4A-E). We further examined 
expression signatures and ATAC-Seq under these steady-state conditions in Vav1-Cre mice 
where hematopoietic cells have consistently undergone heterozygous deletion and external 
perturbations are minimized; we observed little global dysregulation of gene expression or 
chromatin structure (Figure 2.4F-G). In both studies, internal markers (Smc3 expression and 
peaks within the Vav1 locus) served as controls and markers of the expected dynamic range.  
In contrast, under conditions of chimeric competition, Smc3 haploinsufficiency actually led to 
competitive disadvantage in vivo, with progressive population loss over time (Figure 2.5A-F). In 
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these studies, Smc3 deletion was induced using ERT2-Cre following a period of 6 weeks post-
transplant to facilitate engraftment and stem cell homeostasis prior to deletion. Under these 
conditions, activation of ERT2-Cre alone does not lead to stem cell toxicity and competitive 
disadvantage (Figure 2.12A-B), whereas activation of ERT2-Cre just prior to transplantation 
does.32 Analysis of BM populations at the end of the study suggested reduction of populations 
with Smc3 haploinsufficiency across progenitor and mature cell types, eliminating the possibility 
that Smc3 haploinsufficiency led to a profound maturation block that prevented leukocyte 
peripheralization. The competitive disadvantage induced by somatic Smc3 acquisition was 
unexpected. Therefore, we determined whether specific forms of hematopoietic stress might 
enable a competitive advantage that could facilitate stem cell expansion and ultimately enable 
leukemogenesis. We again observed a competitive disadvantage that persisted following a stem 
cell stressor (5-FU exposure) and an inflammatory stressor (pIpC exposure) (Figure 2.5G-J). 
Finally, because SMC3 mutations may not be the first acquired mutation during leukemogenic 
chronicity, we investigated whether Dnmt3a haploinsufficiency might facilitate Smc3 
phenotypes. Germline Dnmt3a haploinsufficiency partially abrogated the myeloid competitive 
disadvantage of somatically acquired Smc3 haploinsufficiency (Figure 2.6), suggesting that 
SMC3 mutations may require pre-existing cooperating mutations to facilitate their action. 
Additionally, these studies do not eliminate the possibility that the frequently observed SMC3 
missense mutations may possess novel gain-of-function activity not accessed in these Smc3 
haploinsufficient studies.  
Thus, under conditions of homeostasis, where all hematopoietic cells have Smc3 
haploinsufficiency, murine Smc3 haploinsufficiency does not appear to grossly dysregulate 
hematopoietic feedback mechanisms or alter normal hematopoietic maturation or self- renewal 
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ex vivo. However, under conditions of competitive transplantation, we observed a disadvantage 
in hematopoietic cells across both myeloid and lymphoid lineages suggesting reduced cell 
production at a multipotent progenitor level.   
These results contrast with previously published work using either knock-down strategies in 
CD34+ cord blood cells or using Mx1-Cre activation with pIpC. Specifically, knocking down of 
Smc3 using shRNA or RAD21 and SMC1A mutants have been shown to increase self-renewal in 
human cord blood CD34+ HSPCs ex vivo.33, 34 Smc3 haploinsufficiency induced by Mx1-Cre 
exhibited shifts in hematopoietic cell populations, colony forming, and competitive 
transplantation advantage when deleted using Mx1-Cre two weeks after transplantation30. These 
data suggest that differences in the models may interact with the biological consequences of 
Smc3 reduction through yet undefined mechanisms.  
In addition, It is worth noting that other MDS or AML-associated mutations such as U2AF135, 36, 
SRSF237, 38, SF3B139, 40, 41, 42, 43, ASXL144, 45 are associated with having competitive 
disadvantage, which may seem counterintuitive for recurring leukemia mutations observed in 
patients, but appears to be recurrent biology. 
The observed defects in hematopoietic cells with Smc3 deficiency and haploinsufficiency may 
reflect population data from the ExAC database, where germline cohesin mutations are observed 
at lower than expected frequencies, suggesting a significant disadvantage in population fitness. 
No loss-of-function variants are detected in SMC3, SMC1A, STAG2, or RAD21 (based on 
statistical models of case numbers and gene size, the expected numbers of loss-of-function 
variants were 58.5, 32, 42.7, and 21.8, respectively). Missense variants were also significantly 
underrepresented in SMC3, SMC1A, and STAG2, but not in RAD21 (z = 6.25, 6.59, 5.11, and 
2.76; more positive scores indicate fewer variants observed than expected). Of the published 
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AML-associated missense mutations, only 1 is reported in ExAC (K795E occurring in 3/121,384 
alleles), although synonymous changes (R155R, Q367Q, R391R), and alternative amino acid 
changes (N604S and I1001L) are noted.46  
In recent decades, mutations in cohesin complex genes have been associated with genetic 
syndromes, referred to as cohesinopathies. Several important features differ between 
cohesinopathies and AML-associated cohesin mutations. Mutations associated with 
cohesinopathy tend to be in cohesin adapter proteins, such as NILS, HDAC8, and ESCO2, with 
fewer mutations observed in SMC3, SMC1A, RAD21, or STAG2.47 Cohesinopathies are 
associated with facial dysmorphism, cognitive impairment, pre- and post-natal growth delay, and 
multi-organ involvement and the clinical manifestations appear milder in cases with SMC3 and 
SMC1A mutations, compared with NIPBL mutations.48  Hematopoietic alterations have not been 
reported with cohesinopathy, nor has the development of AML. Likewise, the accumulation of 
aneuploidies and other chromosomal aberrations has been a recurrent feature of cohesinopathy, 
whereas this phenotype is largely absent in cohesin mutated AML cases, which typically present 
with normal karyotypes. Intriguingly, copy number gains of STAG2 or SMC1A also have been 
associated with cohesinopathy phenotypes,49, 50, 51 suggesting that there may be a critical window 
of adequate cohesin activity and that alterations in either direction may be detrimental. In 
contrast to these human data, in our mouse model, germline heterozygous Smc3 deletion was 
tolerated using X-linked CMV-Cre, which is expressed during early embryogenesis. The 
heterozygous Smc3+/-/CMV-Cre+/-  female progenies had no obvious developmental defects and 
had normal hematopoietic homeostasis in the bone marrow (Figure 2.10). The normal 
hematopoietic cell numbers and differentials in the mice reflect the maintained hematopoiesis of 
cohesinopathies, whereas the normal number of Smc3 haploinsufficient pups contrasts with the 
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near absence of cohesin mutations in the human population data. This discrepancy may be due to 
differences between mouse and human biology; alternatively, cohesinopathy mutations may be 
associated with gain of function activity not recapitulated with this allele, or activity not related 
directly to the SMC1A/SMC3 complex. 
In summary, we did not observe evidence of impaired differentiation or augmented self-renewal 
ex vivo or in vivo when Smc3 haploinsufficiency was generated using CMV-Cre, ERT2-Cre, and 
Vav1-Cre. Instead, Smc3 haploinsufficiency was associated with competitive disadvantage, with 
an early bias towards phenotypes in the myeloid compartment. In AML patients, SMC3 
mutations are typically early, but not initiating, genetic events. These data also suggest that pre-
existing mutations may be required to enable leukemogenic consequences of SMC3 mutagenesis 
and to permit productive clonal expansion. Future studies are needed to determine the 
combination of cooperating mutations that predispose HSPCs to SMC3-induced leukemic 
transformation and clonal dominance.  
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Figure Legends 
Figure 2.1. Generation of Smc3 conditional deficient mice and allele validation.  
(A) Smc3 haploinsufficient mouse model (Smc3trap/+) was obtained from the European Mouse 
Mutagenesis Program (EUCOMM). Smc3 conditionally deficient mice were generated by 
removing the gene-trap cassette, which retains the loxP sites flanking exon 4 (Smc3fl/+) and 
crossing these mice with either Vav1-Cre+/- or ERT2-Cre+/- to delete the allele (Smc3Δ/+). All 
mice are on the C57BL/6J background. (B) Whole genome sequencing validation of Smc3fl 
integration sites. (C) RNA-Seq data of the Smc3fl/+/Vav1-Cre+/- mice showed 227 transcripts 
spliced from exon 3 to 4 and then 313 transcripts from exon 4 to 5 while 279 transcripts from the 
other allele spliced from exon 3 to 5 (average data from 3 mice). (D) Smc3 haploinsufficiency 
was confirmed by reduced Smc3 level in the bone marrow (BM) cells of the Smc3fl/+/Vav1-Cre+/- 
mice measured using intracellular flow cytometry (n=5). *Denotes statistical significance by t-
test. ***p<0.001. (E) Smc3 level is significantly higher in KLS (Lin-cKit+Sca1+) cells and 
progenitor populations than Lin- and SLAM (Lin-cKit+Sca1+CD48-CD150+). *Denotes 
statistical significance by one-way ANOVA with Turkey’s multiple comparisons test. 
****p<0.0001. 
Figure 2.2. Embryonic hematopoietic Smc3 deletion.  
(A) No Smc3fl/fl/Vav1-Cre+/- pups were observed following Smc3fl/+ and Smc3fl/+/Vav1-Cre+/- 
intercrosses (n=11 litters). *Denotes statistical significance by Chi-square test. ****p<0.0001. 
The E13.5 Smc3fl/fl/Vav1-Cre+/- embryos (B) lacked gross fetal livers but retain (C) normal body 
weight compared with littermates. (D) The E13.5 Smc3fl/fl/Vav1-Cre+/- embryos had decreased 
total fetal liver cells and (E)fetal liver hematopoietic cells (CD45.2+). (F) Myeloid 
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(Gr1+CD11b+) cells were reduced and increased proportions of B220+ and CD3e+ lymphocytes 
were observed in E13.5 Smc3fl/fl/Vav1-Cre+/- fetal livers compared to littermate controls. (C-F) 
n=7 embryos per group, *Denotes statistical significance by one-way (D-E) and two-way (F) 
ANOVA with Turkey’s multiple comparisons test. **p<0.01, ****p<0.0001. 
Figure 2.3. Homozygous somatic Smc3 deletion.  
(A) Smc3fl/fl/ERT2-Cre+/- and Smc3fl/fl littermate control mice were treated with 4 doses of 
tamoxifen (3 mg orally on days 1st, 3rd, 5th, 8th and analyzed on day 8, n = 4 mice in each group) 
(A) Peripheral blood analysis. (B) Body weight and spleen weight. (C) Total number of cells in 
the bone marrow, spleen, and thymus. (D) Analysis of lineage percentages within total bone 
marrow cells. (A-D) n=4 mice per group, *Denotes statistical significance by t-test. *p<0.05, 
**p<0.01, ***p<0.001.  (E) Experimental schema of the Smc3fl/fl/ERT2-Cre+/- competitive 
transplantation. (F) Recipient mice were treated with tamoxifen after 6-week engraftment. After 
tamoxifen-mediated deletion, Smc3 deficient cells were rapidly outcompeted, with earliest cell 
loss in the Gr1+ myeloid compartment, showing as complete competitive disadvantage. 
*Denotes statistical significance by 2-way ANOVA with Turkey’s multiple comparisons test. 
****p<0.0001. (E-F) n=10 mice per group.  
Figure 2.4. Hematopoietic Smc3 haploinsufficiency.  
(A and B) Distribution of bone marrow stem, progenitor, and lineage populations in 
Smc3fl/+/ERT2-Cre+/- and littermate Smc3fl/+ mice following 9 doses of tamoxifen (n=6 mice per 
group). (C) Experimental schema of serial replating assay. (D-E) Colony numbers and average 
cells per colony on indicated week of plating in methylcellulose (n=4 mice per group). *Denotes 
statistical significance by t-test. *p<0.05, **p<0.01. (F) Expression analysis by RNA-Seq data 
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of KL (Lin-cKit+Sca1-) bone marrow cells from Smc3fl/+/Vav1-Cre+/-  compared to wild-type 
cells (n=3 mice per group). (G) Comparison of relative peak intensity identified by ATAC-Seq 
of KL bone marrow cells from relative peak Smc3fl/+/Vav1-Cre+/-  compared to wild-type cells 
(n=3 mice per group)  
Figure 2.5. Competitive transplantation of Smc3 haploinsufficient bone marrow cells.  
(A-F) Competitive repopulation assay using Smc3fl/+/ERT2-Cre+/- BM cells and littermate 
Smc3fl/+ BM cells with competitor CD45.1 x CD45.2 bone marrow cells (3 donor mice per group 
and 10 recipient mice per group). Following 6 weeks of engraftment, equal peripheral chimerism 
was validated and recipient mice were treated with 9 doses of tamoxifen. (B - C) Following 42 
weeks, bone marrow chimerism was analyzed (n=3 mice per group). *Denotes statistical 
significance by t-test, *p<0.05, **p<0.01, ****p<0.0001. (D-F) At interval time-points during 
follow-up peripheral blood chimerism was evaluated within the Gr1, B220, and CD3e 
compartments. *Denotes statistical significance by 2-way ANOVA with Turkey’s multiple 
comparisons test, *p<0.05, **p<0.01, ****p<0.0001. (G-J) Competitive repopulation assay of 
Smc3fl/+/ERT2-Cre+/- BM cells under hematopoietic stresses (n=10). As before, recipient mice 
were treated with 9 doses of tamoxifen after 6-week engraftment. PIpC and 5-FU were given 16 
weeks post-transplant, respectively. *Denotes statistical significance by 2-way ANOVA with 
Turkey’s multiple comparisons test, **p<0.01, ***p<0.001, ****p<0.0001. 
Figure 2.6. Effect of Dnmt3a haploinsufficiency on competitive disadvantage in Smc3 
haploinsufficient BM cells.  
(A-D) Competitive repopulation assay of Smc3fl/+/ERT2-Cre+/-/Dnmt3a+/- BM cells and indicated 
littermate controls (n=10 mice per group). As in Figure 2.5, total bone marrow cells were 
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allowed to engraft for 6 weeks and equivalent chimerism was validated before treatment of all 
cohorts with 9 doses of tamoxifen (3 mg/day). Peripheral blood chimerism was evaluated by 
flow cytometry at indicated time points. (E) Bone marrow chimerism assessed by flow cytometry 
26 weeks after engraftment. KL: Lin-cKit+Sca1-. (n=4 mice in each group). *Denotes statistical 
significance by 2-way ANOVA with Turkey’s multiple comparisons test. *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
Figure 2.7. Splicing analysis of exon 3 to exon 5 in wild-type and Smc3fl/+/Vav1-Cre+/- KL 
cells.  
Lin-cKit+Sca1- bone marrow cells were subjected to RNA-Seq (Figure 2.1C and 2.4F). Schema 
indicates total number of reads spanning each splice junction from indicated mice. 
Figure 2.8. Representative plot of intracellular flow cytometry data (Figure 2.1D-E).  
(A) Percentages of Smc3+ cells (left) and mean fluorescence intensity (MFI) (right) of WBM 
from mice used in Figure 2.1D. (B). Overlay of the two MFI plots. (C) Percentages of Smc3+ 
cells (left) and mean fluorescence intensity (MFI) (right) of lin-, KLS, SLAM, and KL cells from 
mouse used in Figure 2.1E. The height of the peak is proportional to the number of events 
collected. 
Figure 2.9. Analysis of homozygous somatic Smc3 deletion.  
(A) Western blot of Smc3 in total bone marrow cells following 4 doses of tamoxifen in indicated 
mice. (B) Image of spleens from Smc3fl/+/ERT2-Cre+/- and Smc3fl/+ littermate controls following 
4 doses of tamoxifen. (C-D) Proportion of bone marrow cells and thymocytes with indicated 
immunophenotypes following 4 doses of tamoxifen in Smc3fl/+/ERT2-Cre+/-mice and littermate 
66 
 
controls (n=4 mice per group), *Denotes statistical significance by t test, *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
Figure 2.10. Analysis of germline heterozygous Smc3 deletion.  
(A) Numbers of male vs. female pups generated from Smc3fl/fl and CMV-Cre+/- intercrosses (of 
note, CMV-Cre is X-linked). (B-E) Complete blood counts, total number of bone marrow cells, 
percentages of HSPCs, and cells of myeloid (Gr1+ CD11b+), B cells (B220+ CD4-), and 
erythroid cells (Ter119+ CD71+) in Smc3+/-/CMV-Cre+/- females and Smc3fl/+ littermate males, 
(n=4 mice per group). 
Figure 2.11. Immunophenotypic analysis of colonies in serial replating assay ex vivo (Figure 
2.4C-E).  
(A) Percentages of Gr1+ CD11b+ and cKit+ FcΕR1+ cells in the Smc3fl/+ and-Smc3fl/+/ERT2-
Cre+/- colonies week 1-4 respectively (n=4 mice per group). (B) Representative plot of the 
Smc3fl/+ and-Smc3fl/+/ERT2-Cre+/- colonies week 1-4. *Denotes statistical significance by t test, 
*p<0.05. 
Figure 2.12. Competitive transplantation of ERT2-Cre+/- bone marrow cells.  
(A) Competitive repopulation assay using ERT2-Cre+/- BM cells with competitor CD45.1 x 
CD45.2 bone marrow cells (3 donor mice and 5 recipient mice). Following 6 weeks of 
engraftment, equal peripheral chimerism was validated and recipient mice were treated with 9 
doses of tamoxifen. (B) At interval time-points during follow-up peripheral blood chimerism was 
evaluated within the Gr1, B220, and CD3e compartments.   
 
67 
 
Figure 2.1. Generation of Smc3 conditional deficient mice and allele validation. 
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Figure 2.2. Embryonic hematopoietic Smc3 deletion. 
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Figure 2.3. Homozygous somatic Smc3 deletion. 
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Figure 2.4. Hematopoietic Smc3 haploinsufficiency. 
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Figure 2.5. Competitive transplantation of Smc3 haploinsufficient bone marrow cells. 
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Figure 2.6. Effect of Dnmt3a haploinsufficiency on competitive disadvantage in Smc3 
haploinsufficient BM cells. 
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Figure 2.7. Splicing analysis of exon 3 to exon 5 in wild-type and Smc3fl/+/Vav1-Cre+/- KL 
cells. 
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Figure 2.8. Representative plot of intracellular flow cytometry data (Figure 2.1.D-E). 
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Figure 2.9. Analysis of homozygous somatic Smc3 deletion. 
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Figure 2.10. Analysis of germline heterozygous Smc3 deletion. 
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Figure 2.11. Immunophenotypic analysis of colonies in serial replating assay ex vivo (Figure 
2.4.C-E). 
 
 
78 
 
Figure 2.12. Competitive transplantation of ERT2-Cre+/- bone marrow cells. 
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Chapter 3: 
Exome analysis of treatment-related AML after APL suggests secondary evolution 
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Treatment-related acute myeloid leukemia (tAML) and treatment-related myelodysplastic 
syndrome (tMDS) have been associated with many types of chemotherapy and radiation.1 
Treatment-related AML or tMDS have been observed after treatment of acute promyelocytic 
leukemia (APL) with combination all-trans retinoic acid (ATRA)/idarubicin/cytarabine.2, 3, 4, 5, 6 
It is unknown whether tAML will emerge following exposure to all-trans retinoic acid (ATRA) 
and arsenic trioxide (ATO), which should not cause DNA damage or the clonal selection of 
chemotherapy-resistant clones that give rise to tAML.1, 6, 7 We describe a case of an older women 
who presented initially with dysplasia. Shortly thereafter she developed APL and was treated 
with ATRA/ATO. Five years later she developed what clinically appeared to be tAML. Exome 
sequencing revealed a founding clone with a TET2 mutation and shared passenger mutations that 
existed at all three time points. The APL sample shared these mutations, and the subsequent 
“tAML” emerged as a new subclone with an NPM1 mutation, more consistent of secondary 
AML rather than tAML. This case demonstrates that APL may emerge within the context of 
clonal hematopoiesis, and that tAML emerging after ATRA/ATO should be evaluated for 
features consistent with secondary AML. 
An 81 year-old woman presented initially with cytopenias at an outside facility. A bone marrow 
biopsy was performed, revealing trilineage dysplasia, 6% promyelocytes, and a normal 
karyotype, 46 XX[20/20] (Table 3.1). Two months later, the cytopenias persisted and a repeat 
bone marrow aspirate was hypercellular with 50% promyelocytes. Cytogenetics revealed 46 XX, 
t(15;17)[18]/46 XX[2] and 89% of cells were positive for PML-RARA by FISH. She was referred 
to Washington University. The bone marrow biopsy was repeated and banked with appropriate 
consent for genomic analysis. The repeat biopsy was unfortunately hemodilute with 4.5% 
t(15;17) by FISH [9/200], was not evaluated by cytomorphology, and RT-PCR failed (control 
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GAPDH primers did not amplify). She was treated with ATRA/ATO. Bone marrow biopsy 6 
weeks later revealed 1% promyelocytes and normal karyotype by cytogenetics and FISH. Due to 
her age, no further bone marrow biopsies were performed and subsequent peripheral blood RT-
PCR tests were negative. Five years later she became increasingly cytopenic and a bone marrow 
aspirate revealed acute myeloid leukemia with 72% blasts, 20% promyelocytes, and a normal 
karyotype. She was treated with decitabine. She deteriorated during the first cycle and 
transitioned to hospice. 
Exome sequencing was performed on three samples using techniques described elsewhere and 
compared against a skin sample, which was used as a germline control (Figure 3.1).8 Cells 
retained on a coverslip were available from the dysplastic pre-APL sample and this was used for 
genomic analysis. No coverslip or other material was available from the APL sample with 89% 
PML-RARA. Cryopreserved bone marrow aspirate cells were used for APL (4.5% PML-RARA) 
and AML (72% blasts) analysis. The collected APL sample only generated one cryovial, which 
was used for DNA synthesis. Unfortunately, no additional samples are available for RNA-Seq 
analysis or sequencing of subpopulations after flow sorting.  
A shared founding clone existed across all three time points that contained a TET2 mutation and 
15 additional variants (Figure 3.1, black). Three additional clusters were identified: 1) variants 
that were present predominantly in the dysplasia sample (SEMA4A, and ZBTB7A, orange); 2) 
variants that were absent in the AML sample (TET1, SACM1L, OR7D2, SH3TC1, blue); 3) 
variants that increased in the AML sample, but were present at low variant allele frequencies or 
were undetected in prior samples (NPM1 and 13 additional variants, red).  
Treatment-related AML has been associated with APL therapy that includes alkylating agents,2, 3, 
4, 9 but has not been associated with ATRA/ATO, which are non-cytotoxic and do not damage 
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DNA. This unusual case initially appeared consistent with tAML following ATRA/ATO, 
however, following exome analysis, appears to be more consistent with a pre-existing dominant 
clone associated with dysplasia and a TET2 mutation, and an NPM1-associated secondary AML. 
Two models are possible (Figure 3.1F). First, the APL may have emerged as a subclone of the 
TET2 founding clone. Given the high TET2 variant allele frequency (VAF, consistent with 70% 
and 66% tumor burden in the dysplastic and APL samples, respectively) and the high tumor 
burden of PML-RARA in the bone marrow (85%), this model seems likely. Alternatively, 
because the sequenced APL sample is hemodilute, it is possible that the PML-RARA clone is 
independent of the TET2 clone, that the APL clone did not peripheralize, or that geographical 
heterogeneity existed in this older patient. Given the absence of additional samples, it is 
impossible to determine whether the APL emerged as a subclone of the TET2 founding clone 
occurred independent of the TET2 clone.  
In order to determine if these subclonal patterns are observed in other APL patients, we reviewed 
available cytogenetic results from published APL patients. Two cases of disease progression 
from MDS to APL have been described10, and cases of treatment-related APL have been 
described following MDS.11 In the former cases, like this case, the timeline of evolution and 
dysplastic changes in the APL morphology suggests that the APL clone likely was evolutionarily 
related to the MDS clone. In the latter cases, the cytogenetics and timeline suggest the APL clone 
likely emerged independent of the MDS clone. 
Clonal hematopoiesis of indeterminate potential (CHIP) and MDS have been associated with 
deletions involving chromosomes 5 and 712, 13, which occasionally co-occur with t(15;17).14, 15, 16 
Therefore, we examined the subclonal relationship of t(15;17) with possible CHIP-related 
variants among APL patients enrolled at large cancer centers. We identified 44 APL cases with 
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t(15;17) and cytogenetic abnormalities in chromosomes 5 or 7. Five cases involved chromosome 
5, two of which also had abnormalities in chromosome 7. Thirty-three cases involved a 
monoclonal process, suggesting that the variants in chromosomes 5 or 7 co-occurred with 
t(15;17). Of the eleven cases with identified polyclones, the chromosome 5 or 7 variant was in a 
subclone of t(15;17) in ten cases and in only one case was there evidence of del(7) in a clone that 
was independent of the t(15;17) clone (Patient 52009 from APL 2006, 46, XY, t(15,17)(q22, 
q11)[13]/46, XY, del(7)(q35)[5]/46, XY [2]) (Table 3.2). These data suggest that t(15;17) may 
co-occur with additional cytogenetic deletions of chromosomes 5 and 7, but t(15;17) is almost 
invariably the founding event, and it is unusual for a concurrent CHIP or MDS clone to co-exist 
with t(15;17). 
Other investigators have reviewed the outcomes in APL patients with cytogenetic abnormalities 
that occur in addition to t(15;17).16, 17, 18 The most recurrently observed co-occurring cytogenetic 
abnormalities include +8 and +21, both of which frequently can be identified as subclonal 
progression events when analyzing metaphase cytogenetics or FISH, and have been observed as 
progression events in MDS and AML.11 In these studies, additional cytogenetic abnormalities 
have not correlated with initial clinical characteristics, or with outcomes in patients with 
t(15;17).16, 17, 18 
Morphologic disease switching also has been described in NPM1-mutated AML patients who 
subsequently developed MDS or myelofibrosis. In each of these cases, the NPM1-mutation was 
lost, and the MDS or myelofibrosis evolved from an antecedent clone with a mutation in TET2, 
JAK2, ASXL1, IDH2, or a spliceosome trancript, suggesting that the two clonal diseases were 
related through an ancestral clone.19 
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In summary, we present a case of what initially appeared to be tAML following non-cytotoxic 
ATRA/ATO therapy for APL. Exome analysis clearly demonstrated a TET2-associated, 
dominant clonal process that anteceded the APL diagnosis, persisted, and gave rise to AML 
associated with evolutionary expansion of an NPM1-mutated subclone. This progression would 
be more consistent with a secondary AML process, rather than a treatment-related process. 
Additional characterization of this case would be interesting. Unfortunately, samples for such 
analyses are unavailable. Review of additional cytogenetic abnormalities observed in APL 
patients did identify one rare case with del(7) independent of the APL clone, suggesting that 
APL can co-exist with CHIP or MDS clones, although it appears much more common for such 
cytogenetic abnormalities to occur as subclones of the APL clone. Collectively, these results 
suggest that caution must be exercised when interpreting the development of tAML following 
ATRA/ATO therapy, and subclonal expansion of related or well-established clones should be 
considered, especially in older patients. 
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Figure Legends 
 
Figure 3.1. Exome analysis of patient 10DD-1029.  
(A) Summary results of all somatic variants detected at any of the three time points analyzed. (B) 
Cluster of variants with stable VAFs across all three samples. (C) Cluster of variants present in 
the initial dysplastic sample, with reduced VAFs in subsequent samples. (D) Cluster of variants 
with VAFs in the initial two samples, but which were absent in the subsequent AML sample. (E) 
Cluster of variants associated with the AML progression, which were largely absent in the initial 
two samples. (F) Two models for subclonal expansion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
91 
 
Figure 3.1. Exome analysis of patient 10DD-1029.  
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Tables 3.1. Clinical data of the patient. 
 
  
Dysplasia APL APL (banked) post-APL AML 
Day 0 Day 49 Day 51 Day 87 Day 1897 
Sequencing exome ND Exome ND exome 
t(15;17) 0% 89% 4.5% 0% 0% 
BM blasts 0% 1% ND 1% 72% 
BM promyelocytes 6% 50% ND 1% 20% 
BM myelocytes 9% 25% ND 25% 1% 
BM metamyelocytes 2% 3% ND 3% 5% 
BM bands 9% 2% ND 2% 0% 
BM dysplasia trilineage atypia ND none none 
PB WBC NA 0.9 0.9 0.9 2.2 
PB % Lymphs NA 95% 95% 95% 88% 
PB % Blasts NA 0% 0% 0% 6% 
 
AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; BM, bone marrow; NA, not 
available; ND, not done; PB, peripheral blood; WBC, white blood cells. 
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Table 3.2. APL patients with cytogenetic abnormalities in chromosomes 5 or 7 and 
evaluable subclonal architecture. 
 
Source Patient Karyotype 
t(15;17) 
subclone 
Clone 
independent 
of t(15;17) 
APL 2006  52009 
46, XY, t(15,17) (q22, q11) [13] / 46, 
XY, del(7)(q35)[5]/46, XY [2]   del(7) 
MD Anderson NA 
46,XX,add(7)(q32),t(15;17)(q24;q21)[5]
/47,idem,+8[2]/46,XX,del(7)(q22q34),t(
15;17)[7]/ 
46,XX,add(4)(p16),t(15;17)[5]/46, 
XX[1] 
del(7), 
+8, 
add(4)   
APL 2006  78034 t(15 ;17), +8 [ ?], t(15 ;17), -7, -5 [ ?] -7, -5, +8   
APL92 848 
46XY,15q+,17q- [19/20] / 45,XY,-
5,15q+,17q- [1/20] -5   
APL92 108 
46,XX,1p-,7q-,15q+,17q-,19q+ [14/20] / 
46,XX,15q+,17q- [6/20]  
del(1p), 
del(7q), 
add(19q)   
APL92 687 
46,XX,t(15;17)(q22;q11～21) [19/20] / 
46,idem,-7,+mar [1/20] -7   
APL92 742 
46,XX,t(15;17) [16/17] / 
46,idem,add(7)(q?) [1/17] add(7)   
MD Anderson NA 
46,XX,t(15;17)(q24;q21)[15]/ 
46,idem,del(7)(q22q32)[3]; 46,XX[2] del(7)   
MD Anderson NA 
46XX,t(15;17)(q22;q21.1)[16]/46, 
idem,del(7)(q22q34)[1]/ 46XX[3] del(7)   
MD Anderson NA 
46XY,t(15;17)(q22;q21)[16]/46,idem,de
l(7)(q32q36)[1]/46,XY[3];  del(7)   
MD Anderson NA 
46XX, del(7)(q31q36), 
inv(9)(p11;q12),t(15;17)(q22;q21)[2]/47
XX,+8,inv(9), der(15), der(17)[3]/46XX, 
inv(9).  
del(7), 
+8   
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